U.S. patent application number 14/480365 was filed with the patent office on 2014-12-25 for hla-dr binding peptides and their uses.
The applicant listed for this patent is Mayo Foundation for Medical Education and Research, University of Washington. Invention is credited to Melanie Beebe, Mary L. Disis, John D. Fikes, Glenn Ishioka, Keith L. Knutson.
Application Number | 20140377340 14/480365 |
Document ID | / |
Family ID | 40591749 |
Filed Date | 2014-12-25 |
United States Patent
Application |
20140377340 |
Kind Code |
A1 |
Knutson; Keith L. ; et
al. |
December 25, 2014 |
HLA-DR BINDING PEPTIDES AND THEIR USES
Abstract
The present invention provides HLA-DR (MHC class II) binding
peptides derived from the ovarian/breast cancer associated
antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu),
Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding
Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be
used in cancer vaccines.
Inventors: |
Knutson; Keith L.; (Fort
Pierce, FL) ; Disis; Mary L.; (Renton, WA) ;
Fikes; John D.; (San Diego, CA) ; Beebe; Melanie;
(Apex, NC) ; Ishioka; Glenn; (San Diego,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Mayo Foundation for Medical Education and Research
University of Washington |
Rochester
Seattle |
MN
WA |
US
US |
|
|
Family ID: |
40591749 |
Appl. No.: |
14/480365 |
Filed: |
September 8, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12740562 |
Aug 24, 2010 |
|
|
|
PCT/US2008/081799 |
Oct 30, 2008 |
|
|
|
14480365 |
|
|
|
|
60984646 |
Nov 1, 2007 |
|
|
|
Current U.S.
Class: |
424/450 ;
424/185.1 |
Current CPC
Class: |
C07K 14/71 20130101;
A61K 38/00 20130101; A61P 37/04 20180101; C07K 7/08 20130101; C07K
14/70503 20130101; A61K 2039/572 20130101; C07K 14/4738 20130101;
C07K 14/4743 20130101; A61P 35/00 20180101; C07K 14/4748
20130101 |
Class at
Publication: |
424/450 ;
424/185.1 |
International
Class: |
C07K 14/71 20060101
C07K014/71 |
Goverment Interests
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under grant
numbers CA107590 and CA015083 awarded by the National Institutes of
Health. The government has certain rights in the invention.
Claims
1. (canceled)
2. A method for eliciting an immune response to a tumor antigen
within a mammal, wherein said method comprises administering a
vaccine composition to said mammal, wherein said vaccine
composition comprises an adjuvant and an isolated HLA-DR binding
peptide having the sequence set forth in SEQ ID NO:145, and further
comprises at least one additional peptide having the sequence set
forth in SEQ ID NO:89 or SEQ ID NO:90.
3. The method of claim 2, wherein said mammal is a human.
4. The method of claim 2, wherein said vaccine composition further
comprises a HTL-inducing peptide.
5. The method of claim 2, wherein said vaccine composition further
comprises a CTL peptide.
6. The method of claim 2, wherein said vaccine composition further
comprises a lipid.
7. The method of claim 2, wherein said vaccine composition further
comprises a liposome.
8. The method of claim 2, wherein said vaccine composition further
comprises at least two Carcinoembryonic Antigen (CEA) HTL peptides,
at least two Cyclin D1 HTL peptides, and at least two Insulin
Growth Factor Binding Protein 2 (IGFBP-2) HTL peptides.
9. The method of claim 1, wherein said at least one additional
peptide has the sequence set forth in SEQ ID NO:89.
10. The method of claim 1, wherein said at least one additional
peptide has the sequence set forth in SEQ ID NO:90.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of priority from U.S.
Provisional Application Ser. No. 60/984,646, filed on Nov. 1,
2007.
BACKGROUND OF THE INVENTION
[0003] 1. Field of Invention
[0004] The present invention relates to compositions and methods
for preventing, treating or diagnosing a number of pathological
states such as cancers. In particular, it provides novel peptides
capable of binding selected major histocompatibility complex (MHC)
molecules and induce an immune response.
[0005] MHC molecules are classified as either Class I or Class II
molecules. Class II MHC molecules are expressed primarily on cells
involved in initiating and sustaining immune responses, such as T
lymphocytes, B lymphocytes, dendritic cells, macrophages, etc.
Class II MHC molecules are recognized by helper T lymphocytes and
induce proliferation of helper T lymphocytes and amplification of
the immune response to the particular immunogenic peptide that is
displayed. Complexes between a particular disease-associated
antigenic peptide and class II HLA molecules are recognized by
helper T lymphocytes and induce proliferation of helper T
lymphocytes and amplification of specific CTL and antibody immune
responses.
[0006] A complex of an HLA molecule and a peptidic antigen acts as
the ligand recognized by HLA-restricted T cells (Buus, S. et al.,
Cell 47:1071, 1986; Babbitt, B. P. et al., Nature 317:359, 1985;
Townsend, A. and Bodmer, H., Annu. Rev. Immunol. 7:601, 1989;
Germain, R. N., Annu. Rev. Immunol. 11:403, 1993).
[0007] Peptides of the present invention comprise epitopes that
bind to HLA class II DR molecules. A greater degree of
heterogeneity in both size and binding frame position of the motif,
relative to the N- and C-termini of the peptide, exists for class
II peptide ligands. This increased heterogeneity of HLA class II
peptide ligands is due to the structure of the binding groove of
the HLA class II molecule which, unlike its class I counterpart, is
open at both ends. Crystallographic analysis of HLA class II
DRB*0101-peptide complexes showed that the major energy of binding
is contributed by peptide residues complexed with complementary
pockets on the DRB*0101 molecules. An important anchor residue
engages the deepest hydrophobic pocket (see, e.g., Madden, D. R.
Ann. Rev. Immunol. 13:587, 1995) and is referred to as position 1
(P1). P1 may represent the N-terminal residue of a class II binding
peptide epitope, but more typically is flanked towards the
N-terminus by one or more residues. Other studies have also pointed
to an important role for the peptide residue in the sixth position
towards the C-terminus, relative to P1, for binding to various DR
molecules.
[0008] In the past few years evidence has accumulated to
demonstrate that a large fraction of HLA class I and class II
molecules can be classified into a relatively few supertypes, each
characterized by largely overlapping peptide binding repertoires,
and consensus structures of the main peptide binding pockets. Thus,
peptides of the present invention are identified by any one of
several HLA-specific amino acid motifs, or if the presence of the
motif corresponds to the ability to bind several allele-specific
HLA molecules, a supermotif. The HLA molecules that bind to
peptides that possess a particular amino acid supermotif are
collectively referred to as an HLA "supertype." Because human
population groups, including racial and ethnic groups, have
distinct patterns of distribution of HLA alleles it will be of
value to identify motifs that describe peptides capable of binding
more than one HLA allele, so as to achieve sufficient coverage of
all population groups. The present invention addresses these and
other needs.
[0009] T lymphocytes recognize an antigen in the form of a peptide
fragment bound to the MHC class I or class II molecule rather than
the intact foreign antigen itself Antigens presented by MHC class
II molecules are usually soluble antigens that enter the antigen
presenting cell via phagocytosis, pinocytosis, or receptor-mediated
endocytosis. Once in the cell, the antigen is partially degraded by
acid-dependent proteases in endosomes. The resulting fragments or
peptide associate with the MHC class II molecule after the release
of the CLIP fragment to form a stable complex that is then
transported to the surface for potential recognition by specific
HTLs. See Blum, et al., Crit. Rev. Immunol., 17: 411-17 (1997);
Arndt, et al., Immunol. Res., 16: 261-72 (1997).
[0010] Peptides that bind a particular MHC allele frequently will
fit within a motif and have amino acid residues with particular
biochemical properties at specific positions within the peptide.
Such residues are usually dictated by the biochemical properties of
the MHC allele. Peptide sequence motifs have been utilized to
screen peptides capable of binding MHC molecules (Sette, et al.,
Proc. Nati. Acad. Sci. USA 86:3296 (1989)), and it has previously
been reported that class I binding motifs identified potential
immunogenic peptides in animal models (De Bruijn, et al., Eur. J.
Immunol. 21: 2963-70 (1991); Pamer, et al., Nature 353: 852-955
(1991)). Also, binding of a particular peptide to a MHC molecule
has been correlated with immunogenicity of that peptide (Schaeffer,
et al., Proc. Natl. Acad. Sci. USA 86:4649 (1989)).
[0011] Accordingly, while some MHC binding peptides have been
identified, there is a need in the art to identify novel MHC
binding peptides from tumor associated antigens that can be
utilized to generate an immune response in vaccines against these
targets. Further, there is a need in the art to identify peptides
capable of binding a wide array of different types of MHC molecules
such they are immunogenic in a large fraction a human outbred
population.
[0012] One of the most formidable obstacles to the development of
broadly efficacious peptide-based immunotherapeutics has been the
extreme polymorphism of HLA molecules. Effective coverage of a
population without bias would thus be a task of considerable
complexity if epitopes were used specific for HLA molecules
corresponding to each individual allele because a huge number of
them would have to be used in order to cover an ethnically diverse
population. There exists, therefore, a need to develop peptide
epitopes that are bound by multiple HLA antigen molecules at high
affinity for use in epitope-based vaccines. The greater the number
of HLA antigen molecules bound, the greater the breadth of
population coverage by the vaccine. Analog peptides may be
engineered based on the information disclosed herein and thereby
used to achieve such an enhancement in breadth of population
coverage.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 shows the identification of preexistent immunity to
promiscuous HER-2/neu HLA-DR epitopes. Each panel shows a scatter
gram of the mean numbers of T cells specific for one of the
identified HER-2/neu (see header of each panel) peptides in both
healthy volunteer donors and patients. Each panel represents a
unique peptide and each data point is derived from one individual.
The grey box (i.e. cutoff) delineates the region that constitutes
the mean and two standard deviations calculated from the normal
healthy individuals. The percentages represent the fraction of
patients that had mean T cell values above the cutoff. The peptides
that are circled are those in which a higher fraction of the
patients responded compared to the normal healthy controls. These
peptides are considered to be the best vaccine candidates. However,
it is clear that the rigidness of this approach could potentially
result in many false negatives. For example, while p885 was shown
to be recognized by 25% of patients, p886, a nearly identical
peptide was found to be recognized by only 4%. However, if one
looks at the graph for p886, there is a healthy individual that
showed a robust response. The exclusion of that data point would
have resulted in a patient response rate of 15%, which would have
been consistent with the p885 response. Despite this, we identified
5 candidates to move forward. The fidelity of this approach is
evident from a prior study which has already shown that a HER-2/neu
peptide, p884-899, which encompasses the binding motif of p885, is
an HLA-DR4 epitope.
[0014] FIG. 2 shows the identification of preexistent immunity to
promiscuous CEA HLA-DR epitopes. FIG. 2 is identical to FIG. 1 with
the only exception that CEA is the antigen. Seven candidate
peptides were identified.
[0015] FIG. 3 shows the identification of preexistent immunity to
promiscuous IGFBP2 HLA-DR epitopes. FIG. 3 is identical to FIG. 1
with the only exception that IGFBP2 is the antigen. Four candidate
peptides were identified. Note that only 10 peptides were assessed
as explained in the text above.
[0016] FIG. 4 shows the identification of preexistent immunity to
promiscuous IGFBP2 HLA-DR epitopes. FIG. 4 is identical to FIG. 1
with the only exception that Cyclin D1 is the antigen. Using the
more liberal statistical method, 7 potential epitopes were
identified.
[0017] FIG. 5 shows the that HER-2/neu peptides, p59, p83, p88 and
p885 are naturally processed and presented antigens. IFN-.gamma.
ELISpot analysis of short term T cell lines generated against
HER-2/neu peptides, p53 (Panel A), p83 (Panel B), p88 (Panel C) and
p885 (Panel D). The lines were tested for responses against
respective culture peptides, an irrelevant 15-mer peptide, a
HER-2/neu protein fragment (amino acids 22-122, Panels A-C; amino
acids 676-1255, Panel D), or an irrelevant similar weight protein,
ovalbumin. Each shows the results from two lines established from
two different breast or ovarian cancer patients who had a positive
ELlspot response to the peptide. Each bar is the mean (s.e.m.) of
three replicates.
[0018] FIG. 6 shows that IGFBP2 peptides p17, p22, p249, and p293
are naturally processed peptides. FIG. 6 is identical to FIG. 5
except that the results were obtained using IGFBP-2 derived helper
epitopes.
BRIEF SUMMARY OF THE INVENTION
[0019] The present invention relates to compositions and methods
for preventing, treating or diagnosing a number of pathological
states such as viral diseases and cancers. Thus, provided herein
are novel peptides capable of binding selected major
histocompatibility complex (MHC) molecules and inducing or
modulating an immune response. Some of the peptides disclosed are
capable of binding human class II MHC (HLA) molecules, including
HLA-DR and HLA-DQ alleles. Also provided are compositions that
include immunogenic peptides having binding motifs specific for MHC
molecules. The peptides and compositions disclosed can be utilized
in methods for inducing an immune response, a helper T lymphocyte
(HTL) response, or a cytotoxic T lymphocyte (CTL) response when
administered to a system.
[0020] Epitopes on a number of immunogenic tumor associated
antigens have been identified. The peptides are thus useful in
pharmaceutical compositions for both in vivo and ex vivo
therapeutic and diagnostic applications (e.g., tetramer reagents;
Beckman Coulter).
[0021] The peptides are also useful as epitope-based vaccines. The
epitope-based vaccines preferably have enhanced, typically
broadened, population coverage. The HLA-DR supermotif-bearing
epitopes comprising the vaccine composition preferably bind to more
than one HLA DR supertype molecule with a KD of less than 1000 nM
or 500 nM, and stimulate a HTL response in patients bearing an HLA
DR supertype allele to which the peptide binds.
[0022] Motif-bearing peptides may additionally be used as
diagnostic, rather than immunogenic, reagents to evaluate an immune
response. For example, an HLA-DR supermotif-bearing peptide epitope
may be used prognostically to analyze an immune response for the
presence of specific HTL populations from patients who possess an
HLA DR supertype allele bound by the peptide epitope.
[0023] The binding affinity of a peptide epitope in accordance with
the invention for at least one HLA DR supertype molecule is
preferably determined A preferred peptide epitope has a binding
affinity of less than 1000 nM, or more preferably less than 500 nM
for the at least one HLA DR supertype molecule, and most preferably
less than 50 nM.
[0024] Synthesis of a HLA DR supermotif-containing epitope may
occur in vitro or in vivo. In a preferred embodiment, the peptide
is encoded by a recombinant nucleic acid and expressed in a cell.
The nucleic acid may encode one or more peptides, at least one of
which is an epitope of the invention.
[0025] A peptide epitope of the invention, in the context of an HLA
DR supertype molecule to which it binds, can be contacted, either
in vitro or in vivo, with a cytotoxic T lymphocyte and thereby be
used to elicit a T cell response in an HLA-diverse population.
[0026] An HTL epitope may be comprised by a single peptide.
Further, the HTL epitope may be lipidated, preferably with palmitic
acid, and may be linked by a spacer molecule to another HTL epitope
or a CTL epitope. The epitope may be expressed by a nucleotide
sequence; in a preferred embodiment the nucleotide sequence is
comprised in an attenuated viral host.
[0027] As will be apparent from the discussion below, other
embodiments of methods and compositions are also within the scope
of the invention. Further, novel synthetic peptides produced by any
of the methods described herein are also part of the invention.
[0028] The present invention provides peptides and nucleic acids
encoding them for use in vaccines and therapeutics. The invention
provides methods of inducing a helper T cell response against a
preselected antigen in, a patient, the method comprising contacting
a helper T cell with an immunogenic peptide of the invention. The
peptides of the invention may be derived from a number of tumor
associated antigens. The methods of the invention can be carried
out in vitro or in vivo. In a preferred embodiment the peptides are
contacted with the helper T cell by administering to the patient a
nucleic acid molecule comprising a sequence encoding the
immunogenic peptide.
[0029] The present invention is directed to methods of modulating
the binding of peptide epitopes to HLA class II molecules. The
invention includes a method of modifying binding of an original
peptide epitope that bears a motif correlated with binding to an
HLA molecule, said motif comprising at least one primary anchor
position, said at least one primary anchor position having
specified therefore primary anchor amino acid residues consisting
essentially of two or more residues, said method comprising
exchanging the primary anchor residue of the original peptide
epitope for another primary anchor residue, with the proviso that
the original primary anchor residue is not the same as the
exchanged primary anchor residue. A preferred embodiment of the
invention includes a method where the original primary anchor
residue is a less preferred residue, and the exchanged residue is a
more preferred residue.
[0030] One alternative embodiment of the invention includes a
method of modifying binding of an original peptide epitope that
bears a motif correlated with binding to an HLA molecule, said
motif comprising at least one primary anchor position having
specified therefore at least one primary anchor residue, and at
least one secondary anchor position having specified therefore at
least one secondary residue, said method comprising exchanging the
secondary anchor residue of the original peptide epitope for
another secondary anchor residue, with the proviso that the
original secondary anchor residue is different than the exchanged
amino acid residue. In some cases the original secondary residue is
a deleterious residue and the exchanged residue is a residue other
than a deleterious residue and/or the original secondary anchor
residue is a less preferred residue and the exchanged residue is a
more preferred residue.
[0031] As will be apparent from the discussion below, other methods
and embodiments are also contemplated. Further, novel synthetic
peptides produced by any of the methods described herein are also
part of the invention.
Definitions
[0032] The following definitions are provided to enable one of
ordinary skill in the art to understand some of the preferred
embodiments of invention disclosed herein. It is understood,
however, that these definitions are exemplary only and should not
be used to limit the scope of the invention as set forth in the
claims. Those of ordinary skill in the art will be able to
construct slight modifications to the definitions below and utilize
such modified definitions to understand and practice the invention
disclosed herein. Such modifications, which would be obvious to one
of ordinary skill in the art, as they may be applicable to the
claims set forth below, are considered to be within the scope of
the present invention. If a definition set forth in this section is
contrary to or otherwise inconsistent with a definition set forth
in patents, published patent applications and other publications
and sequences from GenBank and other databases that are herein
incorporated by reference, the definition set forth in this section
prevails over the definition that is incorporated herein by
reference.
[0033] An "HLA supertype or family", as used herein, describes sets
of HLA molecules grouped on the basis of shared peptide-binding
specificities, rather than serologic supertypes based on shared
antigenic determinants. HLA class II molecules that share somewhat
similar binding affinity for peptides bearing certain amino acid
motifs are grouped into HLA supertypes. The terms "HLA
superfamily," "HLA supertype family," "HLA family," and "HLA
xx-like molecules" (where xx denotes a particular HLA type), are
synonyms.
[0034] As used herein, the term "IC.sub.50" refers to the
concentration of peptide in a binding assay at which 50% inhibition
of binding of a reference peptide is observed. Depending on the
conditions in which the assays are run (i.e., limiting MHC proteins
and labeled peptide concentrations), these values may approximate
KD values. It should be noted that IC.sub.50 values can change,
often dramatically, if the assay conditions are varied, and
depending on the particular reagents used (e.g., HLA preparation,
etc.). For example, excessive concentrations of HLA molecules will
increase the apparent measured IC50 of a given ligand.
[0035] Alternatively, binding is expressed relative to a reference
peptide. As a particular assay becomes more, or less, sensitive,
the IC.sub.50's of the peptides tested may change somewhat.
However, the binding relative to the reference peptide will not
change. For example, in an assay run under conditions such that the
IC.sub.50 of the reference peptide increases 10-fold, the IC.sub.50
values of the test peptides will also shift approximately 10-fold.
Therefore, to avoid ambiguities, the assessment of whether a
peptide is a good, intermediate, weak, or negative binder is
generally based on its IC.sub.50, relative to the IC.sub.50 of a
standard peptide.
[0036] As used herein, "high affinity" with respect to peptide
binding to HLA class II molecules is defined as binding with an
K.sub.D (or IC.sub.50) of less than 50 nM. "Intermediate affinity"
is binding with a KD (or IC.sub.50) of between about 50 and about
500 nM. As used herein, "high affinity" with respect to binding to
HLA class II molecules is defined as binding with an KD (or
IC.sub.50) of less than 100 nM. "Intermediate affinity" is binding
with a KD (or IC.sub.50) of between about 100 and about 1000 nM.
Assays for determining binding are described in detail, e.g., in
PCT publications WO 94/20127 and WO 94/03205.
[0037] Binding may also be determined using other assay systems
including those using: live cells (e.g., Ceppellini et al., Nature
339:392 (1989); Christnick et al., Nature 352:67 (1991); Busch et
al., Int. Immunol. 2:443 (1990); Hill et al.., J Immunol. 147:189
(1991); del Guercio et al., J Immunol. 154:685 (1995)), cell free
systems using detergent lysates (e.g., Cerundolo et al., J Immunol.
21 :2069 (1991)), immobilized purified MHC (e.g., Hill et al., J
Immunol. 152,2890 (1994); Marshall et al., J Immunol. 152:4946
(1994)), ELISA systems (e.g., Reay et al., EMBO J 11 :2829 (1992)),
surface plasmon resonance (e.g., Khilko et al., J Biol. Chem.
268:15425 (1993)); high flux soluble phase assays (Hammer et al.,
J. Exp. Med. 180:2353 (1994)).
[0038] The term "peptide" is used interchangeably with
"oligopeptide" in the present specification to designate a series
of residues, typically L-amino acids, connected one to the other
typically by peptide bonds between the alpha-amino and carbonyl
groups of adjacent amino acids. In certain embodiments, the
oligopeptides of the invention are less than about 50 residues in
length and usually consist of between about 6 and about 25
residues, preferably 14 or 15 residues. Further, an oligopeptide of
the invention can be such that it does not comprise more than 50
contiguous amino acids of a native antigen. The preferred
HTL-inducing peptides of the invention are 30 residues or less in
length, sometimes 20 residues or less and usually consist of
between about 6 and about 25 residues, preferably 14 or 15
residues.
[0039] "Synthetic peptide" refers to a peptide that is not
naturally occurring, but is man-made using such methods as chemical
synthesis or recombinant DNA technology.
[0040] The nomenclature used to describe peptide compounds follows
the conventional practice wherein the amino group is presented to
the left (the N-terminus) and the carboxyl group to the right (the
C-terminus) of each amino acid residue. In the formulae
representing selected specific embodiments of the present
invention, the amino- and carboxyl-terminal groups, although not
specifically shown, are in the form they would assume at
physiologic pH values, unless otherwise specified. In the amino
acid structure formula, each residue is generally represented by
standard three letter or single letter designations. The L-form of
an amino acid residue is represented by a capital single letter or
a capital first letter of a three-letter symbol, and the D-form for
those amino acids having D-forms is represented by a lower case
single letter or a lower case three letter symbol. Glycine has no
asymmetric carbon atom and is simply referred to as "Gly" or G.
Symbols for each amino acids are shown below:
TABLE-US-00001 TABLE 1 Amino acids with their abbreviations Three
letter Single letter Amino acid code code Alanine Ala A Arginine
Arg R Asparagine Asn N Aspartic acid Asp D Cysteine Cys C Glutamine
Gln Q Glutamic acid Glu E Glycine Gly G Histidine His H Isoleucine
Ile I Leucine Leu L Lysine Lys K Methionine Met M Phenylalanine Phe
F Proline Pro P Serine Ser S Threonine Thr T Tryptophan Trp W
Tyrosine Tyr Y Valine Val V
[0041] With regard to a particular amino acid sequence, an
"epitope" is a set of amino acid residues which is involved in
recognition by a particular immunoglobulin, or in the context of T
cells, those residues necessary for recognition by T cell receptor
proteins and/or Major Histocompatibility Complex (MHC) receptors.
In an immune system setting, in vivo or in vitro, an epitope is the
collective features of a molecule, such as primary, secondary and
tertiary peptide structure, and charge, that together form a site
recognized by an immunoglobulin, T cell receptor or HLA molecule.
Throughout this disclosure epitope and peptide are often used
interchangeably.
[0042] It is to be appreciated that protein or peptide molecules
that comprise an epitope of the invention as well as additional
amino acid(s) are still within the bounds of the invention. In
certain embodiments, there is a limitation on the length of a
peptide of the invention. The embodiment that is length-limited
occurs when the protein/peptide comprising an epitope of the
invention comprises a region (i.e., a contiguous series of amino
acids) having 100% identity with a native sequence. In order to
avoid the definition of epitope from reading, e.g., on whole
natural molecules, there is a limitation on the length of any
region that has 100% identity with a native peptide sequence. Thus,
for a peptide comprising an epitope of the invention and a region
with 100% identity with a native peptide sequence, the region with
100% identity to a native sequence generally has a length of: less
than or equal to 600 amino acids, often less than or equal to 500
amino acids, often less than or equal to 400 amino acids, often
less than or equal to 250 amino acids, often less than or equal to
100 amino acids; often less than or equal to 85 amino acids, often
less than or equal to 75 amino acids, often less than or equal to
65 amino acids, and often less than or equal to 50 amino acids. In
certain embodiments, an "epitope" of the invention is comprised by
a peptide having a region with less than 51 amino acids that has
100% identity to a native peptide sequence, in any increment down
to 5 amino acids.
[0043] Accordingly, peptide or protein sequences longer than 600
amino acids are within the scope of the invention, so long as they
do not comprise any contiguous sequence of more than 600 amino
acids that have 100% identity with a native peptide sequence. For
any peptide that has five contiguous residues or less that
correspond to a native sequence, there is no limitation on the
maximal length of that peptide in order to fall within the scope of
the invention. It is presently preferred that a CTL epitope be less
than 600 residues long in any increment down to eight amino acid
residues.
[0044] A "dominant epitope" induces an immune response upon
immunization with whole native antigens which comprise the epitope.
(See, e.g., Sercarz, et al., Annu. Rev. Immunol. 11:729-766
(1993)). Such a response is cross-reactive in vitro with an
isolated peptide epitope.
[0045] A "cryptic epitope" elicits a response by immunization with
isolated peptide, but the response is not cross-reactive in vitro
when intact whole protein which comprises the epitope is used as an
antigen.
[0046] A "subdominant epitope" is an epitope which evokes little or
no response upon immunization with whole antigens which comprise
the epitope, but for which a response can be obtained by
immunization in vivo or in vitro with an isolated epitope, and this
response (unlike the case of cryptic epitopes) is detected when
whole protein is used to recall the response in vitro.
[0047] A "pharmaceutical excipient" comprises a material such as an
adjuvant, a carrier, pH-adjusting and buffering agents, tonicity
adjusting agents, wetting agents, preservatives, and the like.
[0048] As used herein, the term "pharmaceutically acceptable"
refers to a generally non-toxic, inert, and/or physiologically
compatible composition.
[0049] As used herein, the term "protective immune response" or
"therapeutic immune response" refers to a HTL and/or a CTL response
to a tumor associated antigen, which in some way prevents or at
least partially arrests disease symptoms, side effects or
progression. The immune response may include an antibody response
that has been facilitated by the stimulation of helper T cells.
[0050] In certain embodiments, an "immunogenic peptide" is a
peptide which comprises an allele-specific motif such that the
peptide will bind an MHC (HLA) molecule and induce a HTL response
Immunogenic peptides of the invention are capable of binding to an
appropriate class II MHC molecule (e.g., HLA-DR) and inducing a
helper T cell response against the antigen from which the
immunogenic peptide is derived.
[0051] An "immunogenic response" includes one that stimulates a HTL
and/or CTL response in vitro and/or in vivo as well as modulates an
ongoing immune response through directed induction of cell death
(or apoptosis) in specific T cell populations.
[0052] Immunogenic peptides of the invention are capable of binding
to an appropriate HLA-DR molecule and inducing a helper T-cell
response against the antigen from which the immunogenic peptide is
derived. The immunogenic peptides of the invention are less than
about 50 residues in length, often 30 residues or less in length,
or 20 residues or less in length and usually consist of between
about 6 and about 25 residues, preferably 14 or 15 residues.
[0053] The term "derived" when used to discuss an epitope is a
synonym for "prepared." A derived epitope can be isolated from a
natural source, or it can be synthesized in accordance with
standard protocols in the art. Synthetic epitopes can comprise
artificial amino acids "amino acid mimetics," such as D isomers of
natural occurring L amino acids or non-natural amino acids such as
cyclohexylalanine. A derived/prepared epitope can be an analog of a
native epitope.
[0054] Immunogenic peptides are conveniently identified using the
binding motif algorithms described for the specific HLA subtype
(e.g., HLA-DR). The algorithms are mathematical procedures that
produce a score which enables the selection of immunogenic
peptides. Typically one uses the algorithmic score with a "binding
threshold" to enable selection of peptides that have a high
probability of binding at a certain affinity and will in turn be
immunogenic. The algorithm is based upon either the effects on MHC
binding of a particular amino acid at a particular position of a
peptide or the effects on binding of a particular substitution in a
motif containing peptide.
[0055] The term "residue" refers to an amino acid or amino acid
mimetic incorporated into an oligopeptide by an amide bond or amide
bond mimetic.
[0056] A "conserved residue" is an amino acid which occurs in a
significantly higher frequency than would be expected by random
distribution at a particular position in a peptide. Typically a
conserved residue is one where the MHC structure may provide a
contact point with the immunogenic peptide. At least one to three
or more, preferably two, conserved residues within a peptide of
defined length defines a motif for an immunogenic peptide. These
residues are typically in close contact with the peptide binding
groove, with their side chains buried in specific pockets of the
groove itself Typically, an immunogenic peptide will comprise up to
three conserved residues, more usually two conserved residues.
[0057] The term "motif" refers to the pattern of residues in a
peptide of defined length, usually about 6 to about 25 amino acids,
which is recognized by a particular MHC allele (one or more HLA
molecules). The peptide motifs are typically different for each
human MHC allele and differ in the pattern of the highly conserved
residues and negative residues. Peptide motifs are often unique for
the protein encoded by each human HLA allele, differing in their
pattern of the primary and secondary anchor residues. Typically as
used herein, a "motif" refers to that pattern of residues which is
recognized by an HLA molecule encoded by a particular allele. The
binding motif for an allele can be defined with increasing degrees
of precision.
[0058] The designation of a residue position in an epitope as the
"carboxyl terminus" or the "carboxyl terminal position" refers to
the residue position at the end of the epitope which is nearest to
the carboxyl terminus of a peptide, which is designated using
conventional nomenclature as defined below. The "carboxyl terminal
position" of the epitope may or may not actually correspond to the
end of the peptide or polypeptide.
[0059] The designation of a residue position in an epitope as
"amino terminus" or "amino-terminal position" refers to the residue
position at the end of the epitope which is nearest to the amino
terminus of a peptide, which is designated using conventional
nomenclature as defined below. The "amino terminal position" of the
epitope may or may not actually correspond to the end of the
peptide or polypeptide.
[0060] A "motif bearing peptide" or "peptide which comprises a
motif" refers to a peptide that comprises primary anchors specified
for a given motif or supermotif.
[0061] In certain embodiments, a "supermotif" is a peptide binding
specificity shared by HLA molecules encoded by two or more HLA
alleles. Preferably, a supermotif-bearing peptide is recognized
with high or intermediate affinity (as defined herein) by two or
more HLA molecules or antigens.
[0062] Alternatively, the term "supermotif" refers to motifs that,
when present in an immunogenic peptide, allow the peptide to bind
more than one HLA antigen. The supermotif preferably is recognized
with high or intermediate affinity (as defined herein) by at least
one HLA allele having a wide distribution in the human population,
preferably recognized by at least two alleles, more preferably
recognized by at least three alleles, and most preferably
recognized by more than three alleles.
[0063] "Human Leukocyte Antigen" or "HLA" is a human class I or
class II Major Histocompatibility Complex (MHC) protein (see,
Stites, et al., IMMUNOLOGY, 8.sup.TH ED., Lange Publishing, Los
Altos, Calif. (1994).
[0064] "Major Histocompatibility Complex" or "MHC" is a cluster of
genes which plays a role in control of the cellular interactions
responsible for physiologic immune responses. In humans, the MHC
complex is also known as the HLA complex. For a detailed
description of the MHC and HLA complexes, see, Paul, FUNDAMENTAL
IMMUNOLOGY, 3.sup.RD ED., Raven Press, New York, 1993.
[0065] The phrases "isolated" or "biologically pure" refer to
material which is substantially or essentially free from components
which normally accompany it as found in its native state. Thus, the
peptides of this invention do not contain materials normally
associated with their in situ environment, e.g., MHC class II
molecules on antigen presenting cells. Even where a protein has
been isolated to a homogenous or dominant band, there are trace
contaminants in the range of 5-10% of native protein which
co-purify with the desired protein. Isolated peptides of this
invention do not contain such endogenous co-purified protein.
[0066] "Peripheral blood mononuclear cells" (PBMCs) are cells found
in from the peripheral blood of a patient. PBMCs comprise, e.g.,
CTLs and HTLs and antigen presenting cells. These cells can contact
an antigen in vivo, or be obtained from a mammalian source and
contacted with an antigen in vitro.
[0067] "Cross-reactive binding" indicates that a peptide is bound
by more than one HLA molecule; a synonym is degenerate binding.
[0068] "Promiscuous recognition" is where the same peptide bound by
different HLA molecules is recognized by the same T cell clone. It
may also refer to the ability of a peptide to be recognized by a
single T cell receptor in the context of multiple HLA alleles.
[0069] "Link" or "join" refers to any method known in the art for
functionally connecting peptides, including, without limitation,
recombinant fusion, covalent bonding, disulfide bonding, ionic
bonding, hydrogen bonding, and electrostatic bonding.
[0070] A "non-native" sequence or "construct" refers to a sequence
that is not found in nature, i.e., is "non-naturally occurring".
Such sequences include, e.g., peptides that are lipidated or
otherwise modified, and polyepitopic compositions that contain
epitopes that are not contiguous in a native protein sequence.
[0071] As used herein, a "vaccine" is a composition that contains
one or more peptides of the invention, see, e.g., TABLE I. There
are numerous embodiments of vaccines in accordance with the
invention, such as by a cocktail of one or more peptides; one or
more peptides of the invention comprised by a polyepitopic peptide;
or nucleic acids that encode such peptides or polypeptides, e.g., a
minigene that encodes a polyepitopic peptide. The "one or more
peptides" can include any whole unit integer from 1-150, e.g., at
least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40 , 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,
100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 or more
peptides of the invention. The peptides or polypeptides can
optionally be modified, such as by lipidation, addition of
targeting or other sequences. HLA class II-binding peptides of the
invention can be linked to HLA class I-binding peptides, to
facilitate activation of both cytotoxic T lymphocytes and helper T
lymphocytes. Vaccines can comprise peptide pulsed antigen
presenting cells, e.g., dendritic cells.
DETAILED DESCRIPTION OF THE INVENTION
[0072] Certain embodiments of the present invention relate in part
to an epitope-based approach for vaccine design. Such an approach
is based on the well-established finding that the mechanism for
inducing HTL immune response comprises the step of presenting a HTL
epitope as a peptide of about 6-25 amino acids bound to an HLA
molecule displayed on an antigen-presenting cell.
[0073] Certain embodiments of the present invention relate to
peptides comprising allele-specific peptide motifs and supermotifs
which bind to HLA class II molecules.
[0074] As noted above, high HLA binding affinity is correlated with
higher immunogenicity. Higher immunogenicity can be manifested in
several different ways. For instance, a higher binding peptide will
be immunogenic more often. Close to 90% of high binding peptides
are immunogenic, as contrasted with about 50% of the peptides which
bind with intermediate affinity. A higher binding peptide will also
lead to a more vigorous response. As a result, less peptide is
required to elicit a similar biological effect. Thus, in some
embodiments of the invention high binding epitopes are particularly
desired.
[0075] It has been noted that a significant number of epitopes
derived from known non-viral tumor associated antigens (TAA) bind
HLA Class II with intermediate affinity (IC.sub.50 in the 50-500 mM
range). It has been found that 8 of 15 known TAA peptides
recognized by tumor infiltrating lymphocytes (TIL) or CTL bound in
the 50-500 mM range. These data are in contrast with estimates that
90% of known viral antigens that were recognized as peptides bound
HLA with IC.sub.50 of 50 mM or less while only approximately 10%
bound in the 50-500 mM range (Sette, et al., J. Immunol.,
153:5586-5592 (1994)). This phenomenon is probably due in the
cancer setting to elimination, or functional inhibition of the CTL
recognizing several of the highest binding peptides, presumably
because of T cell tolerization events.
[0076] Epitope-bearing peptides in accordance with the invention
can be prepared synthetically, by recombinant DNA technology, or
from natural sources such as whole viruses or tumors. Although the
peptide will preferably be substantially free of other naturally
occurring host cell proteins and fragments thereof, in some
embodiments the peptides are synthetically conjugated to native
molecules or particles; the peptides can also be conjugated to
non-native molecules or particles.
[0077] The peptides in accordance with the invention can be a
variety of lengths, and either in their neutral (uncharged) forms
or in forms which are salts. The peptides in accordance with the
invention are either free of modifications such as glycosylation,
side chain oxidation, or phosphorylation; or they contain these
modifications.
[0078] Desirably, the epitope-bearing peptide will be as small as
possible while still maintaining relevant immunologic activity of
the large peptide; of course it is particularly desirable with
peptides from pathogenic organisms that the peptide be small in
order to avoid pathogenic function. When possible, it may be
desirable to optimize epitopes of the invention to a length of
about 6 to about 25, preferably 14 to 15 amino acid residues for a
class II molecule. Preferably, the peptides are commensurate in
size with endogenously processed viral peptides or tumor cell
peptides that are bound to HLA class I or class II molecules on the
cell surface. Nevertheless, the identification and preparation of
peptides of other lengths can be carried out using the techniques
described here such as the disclosures of primary anchor positions.
It is to be appreciated that peptide epitopes in accordance with
the invention can be present in peptides or proteins that are
longer than the epitope itself Moreover, multiepitopic peptides can
comprise at least one epitope of the invention along with other
epitope(s).
[0079] In particular, the invention provides motifs that are common
to peptides bound by more than one HLA allele. By a combination of
motif identification and MHC-peptide interaction studies, peptides
useful for peptide vaccines have been identified.
[0080] Peptides comprising the epitopes from these antigens are
synthesized and then tested for their ability to bind to the
appropriate MHC molecules in assays using, for example,
immunofluorescent staining and flow microfluorometry,
peptide-dependent class II assembly assays. Those peptides that
bind to the class II molecule are further evaluated for their
ability to serve as targets for HTLs derived from infected or
immunized individuals, as well as for their capacity to induce
primary in vitro or in vivo HTL responses that can give rise to HTL
populations capable of reacting with tumor cells as potential
therapeutic agents.
[0081] The starting point, therefore, for the design of effective
vaccines is to ensure that the vaccine will generate a large number
of epitopes that can successfully be presented. It may be possible
to administer the peptides representing the epitopes per se. Such
administration is dependent on the presentation of "empty" HLA
molecules displayed on the cells of the subject. In one approach to
use of the immunogenic peptides per se, these peptides may be
incubated with antigen-presenting cells from the subject to be
treated ex vivo and the cells then returned to the subject.
[0082] Alternatively, the peptides can be generated in situ by
administering a nucleic acid containing a nucleotide sequence
encoding it. Means for providing such nucleic acid molecules are
described in WO99/58658, the disclosure of which is incorporated
herein by reference. Further, the immunogenic peptides can be
administered as portions of a larger peptide molecule and cleaved
to release the desired peptide. The larger peptide may contain
extraneous amino acids, in general the fewer the better. Thus,
peptides which contain such amino acids are typically 50 amino
acids or less, more typically 30 amino acids or less, and more
typically 20 amino acids or less. The precursor may also be a
heteropolymer or homopolymer containing a multiplicity of different
or same HTL epitopes. Of course, mixtures of peptides and nucleic
acids which generate a variety of immunogenic peptides can also be
employed. The design of the peptide vaccines, the nucleic acid
molecules, or the hetero- or homo-polymers is dependent on the
inclusion of the desired epitope.
[0083] In certain embodiments, it is preferred that peptides
include an epitope that binds to an HLA-DR supertype allele. These
motifs may be used to define T-cell epitopes from any desired
antigen, particularly those associated with human cancers for which
the amino acid sequence of the potential antigen targets is
known.
[0084] The peptides are thus useful in pharmaceutical compositions
for both in vivo and ex vivo therapeutic and diagnostic
applications.
[0085] Peptides comprising the supermotif sequences can be
identified, as noted above, by screening potential antigenic
sources. Useful peptides can also be identified by synthesizing
peptides with systematic or random substitution of the variable
residues in the supermotif, and testing them according to the
assays provided. As demonstrated below, it is useful to refer to
the sequences of the target HLA molecule, as well.
[0086] For epitope-based vaccines, the peptides of the present
invention preferably comprise a supermotif and/or motif recognized
by an HLA class II molecule having a wide distribution in the human
population. The large degree of HLA polymorphism is an important
factor to be taken into account with the epitope-based approach to
vaccine development. To address this factor, epitope selection
encompassing identification of peptides capable of binding at high
or intermediate affinity to multiple HLA molecules is preferably
utilized, most preferably these epitopes bind at high or
intermediate affinity to two or more allele-specific HLA
molecules.
[0087] HTL-inducing peptides of interest for vaccine compositions
preferably include those that have an IC.sub.50 or binding affinity
value for class II HLA molecules, 1000 nM or better (i.e., the
value is greater than or equal to 1000 nM). For example, peptide
binding is assessed by testing the capacity of a candidate peptide
to bind to a purified HLA molecule in vitro. Peptides exhibiting
high or intermediate affinity are then considered for further
analysis. Selected peptides are generally tested on other members
of the supertype family. In preferred embodiments, peptides that
exhibit cross-reactive binding are then used in cellular screening
analyses or vaccines.
[0088] Definition of motifs that are predictive of binding to
specific class II alleles allows the identification of potential
peptide epitopes from an antigenic protein whose amino acid
sequence is known. Typically, identification of potential peptide
epitopes is initially carried out using a computer to scan the
amino acid sequence of a desired antigen for the presence of motifs
and/or supermotifs.
[0089] The previous definition of motifs specific for different
class II alleles allows the identification of potential peptide
epitopes from an antigenic protein whose amino acid sequence is
known. Typically, identification of potential peptide epitopes is
initially carried out using a computer to scan the amino acid
sequence of a desired antigen for the presence of motifs. The
epitopic sequences are then synthesized. The capacity to bind MHC
Class II molecules is measured in a variety of different ways.
[0090] The procedures used to identify peptides of the present
invention generally follow the methods disclosed in Falk et al.,
Nature 351:290 (1991), which is incorporated herein by reference.
Briefly, the methods involve large-scale isolation of MHC class II
molecules, typically by immunoprecipitation or affinity
chromatography, from the appropriate cell or cell line. Examples of
other methods for isolation of the desired MHC molecule equally
well known to the artisan include ion exchange chromatography,
lectin chromatography, size exclusion, high performance ligand
chromatography, and a combination of all of the above
techniques.
[0091] The peptides bound to the peptide binding groove of the
isolated MHC molecules are eluted typically using acid treatment.
Peptides can also be dissociated from class II molecules by a
variety of standard denaturing means, such as heat, pH, detergents,
salts, chaotropic agents, or a combination thereof
[0092] Peptide fractions are further separated from the MHC
molecules by reversed-phase high performance liquid chromatography
(HPLC) and sequenced. Peptides can be separated by a variety of
other standard means well known to the artisan, including
filtration, ultrafiltration, electrophoresis, size chromatography,
precipitation with specific antibodies, ion exchange
chromatography, isoelectrofocusing, and the like.
[0093] Sequencing of the isolated peptides can be performed
according to standard techniques such as Edman degradation
(Hunkapiller, M. W., et al., Methods Enzymol. 91, 399 [1983]).
Other methods suitable for sequencing include mass spectrometry
sequencing of individual peptides as previously described (Hunt, et
al., Science 225:1261 (1992), which is incorporated herein by
reference) Amino acid sequencing of bulk heterogenous peptides
(e.g., pooled HPLC fractions) from different class I molecules
typically reveals a characteristic sequence motif for each class I
allele.
[0094] Next, peptides that test positive in the MHC class II
binding assay are assayed for the ability of the peptides to induce
specific HTL responses in vitro. For instance, antigen-presenting
cells that have been incubated with a peptide can be assayed for
the ability to induce HTL responses in responder cell populations.
Antigen-presenting cells can be normal cells such as peripheral
blood mononuclear cells or dendritic cells (Inaba, et al., J. Exp.
Med. 166:182 (1987); Boog, Eur. J. Immunol, 18:219 (1988)).
[0095] As disclosed herein, higher HLA binding affinity is
correlated with greater immunogenicity. Greater immunogenicity can
be manifested in several different ways. Immunogenicity can
correspond to whether an immune response is elicited at all, and to
the vigor of any particular response, as well as to the extent of a
diverse population in which a response is elicited. For example, a
peptide might elicit an immune response in a diverse array of the
population, yet in no instance produce a vigorous response. In
accordance with the principles disclosed herein, close to 90% of
high binding peptides have been found to be immunogenic, as
contrasted with about 50% of the peptides which bind with
intermediate affinity. Moreover, higher binding affinity peptides
lead to more vigorous immunogenic responses. As a result, less
peptide is required to elicit a similar biological effect if a high
affinity binding peptide is used. Thus, in preferred embodiments of
the invention, high affinity binding epitopes are particularly
useful. Nevertheless, improvements over the prior art are achieved
with intermediate or high binding peptides.
[0096] After determining their binding affinity, additional
confirmatory work can be performed to select, amongst these vaccine
candidates, epitopes with preferred characteristics in terms of
population coverage, antigenicity, and immunogenicity.
[0097] Thus, various strategies can be utilized to evaluate
immunogenicity, including:
[0098] 1) Evaluation of primary T cell cultures from normal
individuals (see, e.g., Wentworth, P. A. et al., Mol. Immunol.
32:603, 1995; Celis, E. et al., Proc. Natl. Acad. Sci. USA 91:2105,
1994; Tsai, V. et al., J. Immunol. 158:1796, 1997; Kawashima, I. et
al., Human Immunol. 59:1, 1998); This procedure involves the
stimulation of peripheral blood lymphocytes (PBL) from normal
subjects with a test peptide in the presence of antigen presenting
cells in vitro over a period of several weeks. T cells specific for
the peptide become activated during this time and are detected.
[0099] 2) Immunization of HLA transgenic mice (see, e.g.,
Wentworth, P. A. et al., J. Immunol. 26:97, 1996; Wentworth, P. A.
et al., Int. Immunol. 8:651, 1996; Alexander, J. et al., J.
Immunol. 159:4753, 1997); In this method, peptides in incomplete
Freund's adjuvant are administered subcutaneously to HLA transgenic
mice. Several weeks following immunization, splenocytes are removed
and cultured in vitro in the presence of test peptide for
approximately one week. Peptide-specific T cells are detected.
[0100] 3) Demonstration of recall T cell responses from patients
who have been effectively vaccinated or who have a tumor; (see,
e.g., Rehermann, B. et al., J. Exp. Med. 181:1047, 1995; Doolan, D.
L. et al., Immunity 7:97, 1997; Bertoni, R. et al., J. Clin.
Invest. 100:503, 1997; Threlkeld, S. C. et al., J. Immunol.
159:1648, 1997; Diepolder, H. M. et al., J. Virol. 71:6011, 1997;
Tsang et al., J. Natl. Cancer Inst. 87:982-990, 1995; Disis et al.,
J Immunol. 156:3151-3158, 1996). In applying this strategy, recall
responses are detected by culturing PBL from patients with cancer
who have generated an immune response "naturally", or from patients
who were vaccinated with tumor antigen vaccines.
[0101] PBL from subjects are cultured in vitro for 1-2 weeks in the
presence of test peptide plus antigen presenting cells (APC) to
allow activation of "memory" T cells, as compared to "naive" T
cells. At the end of the culture period, T cell activity is
detected.
[0102] An immunogenic peptide epitope of the invention may be
included in a polyepitopic vaccine composition comprising
additional peptide epitopes of the same antigen, antigens from the
same source, and/or antigens from a different source. Moreover,
class II epitopes can be included along with class I epitopes.
Peptide epitopes from the same antigen may be adjacent epitopes
that are contiguous in sequence or may be obtained from different
regions of the protein.
[0103] An epitope present in the peptides of the invention can be
cross-reactive or non-cross-reactive in its interactions with MHC
alleles and allele subtypes. Cross-reactive binding of an epitope
(or peptide) permits an epitope to be bound by more than one HLA
molecule. Such cross-reactivity is also known as degenerate
binding. A non-cross-reactive epitope would be restricted to
binding a particular MHC allele or allele subtype.
Motifs Indicative of Class II HTL Inducing Peptide Epitope
[0104] The primary anchor residues of the HLA class II supermotifs
and motifs are delineated below.
HLA DR-1-4-7 Supermotif
[0105] Motifs have also been identified for peptides that bind to
three common HLA class II allele-specific HLA molecules: HLA
DRB1*0401, DRB1*0101, and DRB1*0701 (see, e.g., the review by
Southwood et al. J. Immunology 160:3363-3373,1998). Collectively,
the common residues from these motifs delineate the HLA DR-1-4-7
supermotif. Peptides that bind to these DR molecules carry a
supermotif characterized by a large aromatic or hydrophobic residue
(Y, F, W, L, I, V, or M) as a primary anchor residue in position 1,
and a small, non-charged residue (S, T, C, A, P, V, I, L, or M) as
a primary anchor residue in position 6 of a 9-mer core region.
Allele-specific secondary effects and secondary anchors for each of
these HLA types have also been identified (Southwood et al.,
supra). Peptide binding to HLA-DRB1*0401, DRB1*0101, and/or
DRB1*0701 can be modulated by substitutions at primary and/or
secondary anchor positions, preferably choosing respective residues
specified for the supermotif.
[0106] Two alternative motifs (i.e., submotifs) characterize
peptide epitopes that bind to HLA-DR3 molecules (see, e.g., Geluk
et al., J. Immunol. 152:5742, 1994). In the first motif (submotif
DR3A) a large, hydrophobic residue (L, I, V, M, F, or Y) is present
in anchor position 1 of a 9-mer core, and D is present as an anchor
at position 4, towards the carboxyl terminus of the epitope. As in
other class II motifs, core position 1 may or may not occupy the
peptide N-terminal position.
[0107] The alternative DR3 submotif provides for lack of the large,
hydrophobic residue at anchor position 1, and/or lack of the
negatively charged or amide-like anchor residue at position 4, by
the presence of a positive charge at position 6 towards the
carboxyl terminus of the epitope. Thus, for the alternative
allele-specific DR3 motif (submotif DR3B): L, I, V, M, F, Y, A, or
Y is present at anchor position 1; D, N, Q, E, S, or T is present
at anchor position 4; and K, R, or H is present at anchor position
6. Peptide binding to HLA-DR3 can be modulated by substitutions at
primary and/or secondary anchor positions, preferably choosing
respective residues specified for the motif.
[0108] As with HLA class I binding peptides, motifs have also been
defined for HLA class II-binding peptides. Several studies have
identified an important role for an aromatic or hydrophobic residue
(I, L, M, V, F, W, or Y) at position 1 of a 9-mer core region,
typically nested within a longer peptide sequence, in the binding
of peptide ligands to several HLA-class II alleles (Hammer et al.
Cell 74:197, (1993); Sette et al. J. Immunol. 151:3163-70 (1993);
O'Sullivan et al. J. Immunol. 147:2663 (1991); and Southwood et al.
J. Immunol. 160:3363-73 (1998)). A strong role has also been
demonstrated for the residue in position 6 of the 9-mer core, where
short and/or hydrophobic residues (S, T, C, A, P, V, I, L, or M)
are preferred. This position 1-position 6 motif has been described
as a DR-supermotif (Southwood et al. J. Immunol. 160:3363-3373
(1998)) and has been shown to efficiently identify peptides capable
of binding a large set of common HLA-class II alleles.
[0109] Peptides binding to class II molecules may also be analyzed
with respect to the identification of secondary preferred or
deleterious residues. For example, to derive a more detailed
DRB1*0401 motif to define secondary residues influencing peptide
binding, we employed a strategy similar to that performed with
class I peptides. For each peptide analyzed, nine-residue-long core
regions were aligned on the basis of the primary class II positions
P1 and P6 anchors. Then, the average binding affinity of a peptide
carrying a particular residue was calculated for each position,
relative to the remainder of the group. Following this method,
values showing average relative binding were compiled. These values
also present a map of the positive or negative effect of each of
the 20 naturally occurring amino acids in DRB1*0401 binding
capacity when occupying a particular position relative to the P1-P6
class II motif positions.
[0110] Variations in average relative binding of greater than or
equal to fourfold or less than or equal to 0.25 were arbitrarily
considered significant and indicative of secondary effects of a
given residue on HLA-peptide interactions. Most secondary effects
were associated with P4, P7, and P9. These positions correspond to
secondary anchors engaging shallow pockets on the DR molecule.
Similar studies defining secondary residues were also performed for
DRB1*0101 and DRB1*0701. The definitions of secondary residues of
motifs for DR1, DR4, and DR7 are shown in TABLE 139.
[0111] Upon definition of allele-specific secondary effects and
secondary anchors, allele-specific algorithms were derived and
utilized to identify peptides binding DRB1*0101, DRB1*0401, and
DRB*0701. Further experiments, identified a large set of HLA class
II molecules, which includes at least the DRB1*0101, DRB1*0401, and
DRB*0701, DRB1*1501, DRB1*0901 and DRB1*1302 allelic products
recognizing the DR supermotif, and is characterized by largely
overlapping peptide binding repertoires.
[0112] The data presented above confirm that several common HLA
class II types are characterized by largely overlapping peptide
binding repertoires. On this basis, in analogy to the case of HLA
class I molecules, HLA class II molecules can be grouped in a HLA
class II supertype, defined and characterized by similar, or
largely overlapping (albeit not identical) peptide binding
specificities.
[0113] The peptides present in the invention can be identified by
any suitable method. For example, peptides are conveniently
identified using the algorithms of the invention described in the
co-pending U.S. patent application Ser. No. 09/894,018. These
algorithms are mathematical procedures that produce a score which
enables the selection of immunogenic peptides. Typically one uses
the algorithmic score with a binding threshold to enable selection
of peptides that have a high probability of binding at a certain
affinity and will in turn be immunogenic. The algorithm are based
upon either the effects on MHC binding of a particular amino acid
at a particular position of a peptide or the effects on binding MHC
of a particular substitution in a motif containing peptide.
[0114] Peptide sequences characterized in molecular binding assays
and capture assays have been and can be identified utilizing
various technologies. Motif-positive sequences are identified using
a customized application created at Epimmune. Sequences are also
identified utilizing matrix-based algorithms, and have been used in
conjunction with a "power" module that generates a predicted 50%
inhibitory concentration (PIC) value. These latter methods are
operational on Epimmune's HTML-based Epitope Information System
(EIS) database. All of the described methods are viable options in
peptide sequence selection for IC.sub.50 determination using
binding assays.
[0115] The capacity to bind MHC molecules is measured in a variety
of different ways. One means is a MHC binding assay as described in
the related applications, noted above. Other alternatives described
in the literature include inhibition of antigen presentation
(Sette, et al., J. Immunol. 141:3893 (1991), in vitro assembly
assays (Townsend, et al., Cell 62:285 (1990), and FACS based assays
using mutated cells, such as RMA.S (Melief, et al., Eur. J.
Immunol. 21:2963 (1991)).
[0116] Capture Assay: Unlike the HPLC-based molecular binding
assay, noted above, the high throughput screening ("HTS") Capture
assay does not utilize a size-exclusion silica column for
separation of bound from unbound radioactive marker. Instead, wells
of an opaque white 96-well Optiplate (Packard) are coated with 3
.mu.g (100 .mu.l@ 30 .mu.g/ml) of HLA-specific antibody (Ab) that
"capture" complexes of radiolabeled MHC and unlabeled peptide
transferred from the molecular binding assay plate in 100 .mu.l of
0.05% NP40/PBS. After a 3-hour incubation period, the supernatant
is decanted and scintillation fluid (Microscint 20) added. Captured
complexes are then measured on a microplate scintillation and
luminescence counter (TopCount NXTTM; Packard).
[0117] Additional assays for determining binding are described in
detail, i.e., in PCT publications WO 94/20127 and WO 94/03205.
Binding data results are often expressed in terms of IC.sub.50
value. IC.sub.50 is the concentration of peptide in a binding assay
at which 50% inhibition of binding of a reference peptide occurs.
Given the conditions in which the assays are preformed (i.e.,
limiting MHC proteins and labeled peptide concentrations), these
values approximate K.sub.D values. It should be noted that
IC.sub.50 values can change, often dramatically, if the assay
conditions are varied, and depending on the particular reagents
used (i.e., MHC preparation, etc.). For example, excessive
concentrations of MHC molecules will increase the apparent measured
IC.sub.50 of a given ligand. Alternatively, binding is expressed
relative to a reference peptide. Although as a particular assay
becomes more, or less, sensitive, the IC.sub.50's of the peptides
tested may change somewhat, the binding relative to the reference
peptide will not significantly change. For example, in an assay
preformed under conditions such that the IC.sub.50 of the reference
peptide increases 10-fold, the IC.sub.50 values of the test
peptides will also increase approximately 10-fold. Therefore, to
avoid ambiguities, the assessment of whether a peptide is a good,
intermediate, weak, or negative binder is generally based on its
IC.sub.50, relative to the IC.sub.50 of a standard peptide.
[0118] The peptides of the invention may also comprise isosteres of
two or more residues in the MHC-binding peptide. An isostere as
defined here is a sequence of two or more residues that can be
substituted for a second sequence because the steric conformation
of the first sequence fits a binding site specific for the second
sequence. The term specifically includes peptide backbone
modifications well known to those skilled in the art. Such
modifications include modifications of the amide nitrogen, the
.alpha.-carbon, amide carbonyl, complete replacement of the amide
bond, extensions, deletions or backbone crosslinks. See, generally,
Spatola, Chemistry and Biochemistry of Amino Acids, Peptides and
Proteins, Vol. VII (Weinstein ed., 1983).
[0119] Modifications of peptides with various amino acid mimetics
or unnatural amino acids are particularly useful in increasing the
stability of the peptide in vivo. Stability can be assayed in a
number of ways. For instance, peptidases and various biological
media, such as human plasma and serum, have been used to test
stability. See, e.g., Verhoef et al., Eur. J. Drug Metab.
Pharmacokin. 11:291-302 (1986). Half life of the peptides of the
present invention is conveniently determined using a 25% human
serum (v/v) assay. The protocol is generally as follows. Pooled
human serum (Type AB, non-heat inactivated) is delipidated by
centrifugation before use. The serum is then diluted to 25% with
RPMI tissue culture media and used to test peptide stability. At
predetermined time intervals a small amount of reaction solution is
removed and added to either 6% aqueous trichloracetic acid or
ethanol. The cloudy reaction sample is cooled (4.degree. C.) for 15
minutes and then spun to pellet the precipitated serum proteins.
The presence of the peptides is then determined by reversed-phase
HPLC using stability-specific chromatography conditions.
[0120] Such analogs may also possess improved shelf-life or
manufacturing properties. More specifically, non-critical amino
acids need not be limited to those naturally occurring in proteins,
such as L-.alpha.-amino acids, or their D-isomers, but may include
non-natural amino acids as well, such as amino acids mimetics, e.g.
D- or L- naphylalanine; D- or L-phenylglycine; D- or
L-2-thieneylalanine; D- or L-1,-2, 3-, or 4- pyreneylalanine; D- or
L-3 thieneylalanine; D- or L-(2-pyridinyl)-alanine; D- or
L-(3-pyridinyl)-alanine; D- or L-(2-pyrazinyl)-alanine; D- or
L-(4-isopropyl)-phenylglycine; D-(trifluoromethyl)-phenylglycine;
D-(trifluoromethyl)-phenylalanine; D-p-fluorophenylalanine; D- or
L- p-biphenylphenylalanine; D- or L-
p-methoxybiphenylphenylalanine; D- or L-2-indole(alkyl)alanines;
and, D- or L-alkylalanines, where the alkyl group can be a
substituted or unsubstituted methyl, ethyl, propyl, hexyl, butyl,
pentyl, isopropyl, iso-butyl, sec-isotyl, iso-pentyl, or a
non-acidic amino acids. Aromatic rings of a nonnatural amino acid
include, e.g., thiazolyl, thiophenyl, pyrazolyl, benzimidazolyl,
naphthyl, furanyl, pyrrolyl, and pyridyl aromatic rings.
[0121] Another embodiment for generating effective peptide analogs
involves the substitution of residues that have an adverse impact
on peptide stability or solubility in, e.g., a liquid environment.
This substitution may occur at any position of the peptide epitope.
Analogs of the present invention may include peptides containing
substitutions to modify the physical property (e.g., stability or
solubility) of the resulting peptide. For example, a cysteine (C)
can be substituted out in favor of .alpha.-amino butyric acid. Due
to its chemical nature, cysteine has the propensity to form
disulfide bridges and sufficiently alter the peptide structurally
so as to reduce binding capacity. Substituting .alpha.-amino
butyric acid for C not only alleviates this problem, but actually
improves binding and crossbinding capability in certain instances
(see, e.g., the review by Sette et al., In: Persistent Viral
Infections, Eds. R. Ahmed and I. Chen, John Wiley & Sons,
England, 1999). Substitution of cysteine with .alpha.-amino butyric
acid may occur at any residue of a peptide epitope, i.e. at either
anchor or non-anchor positions.
[0122] The binding activity, particularly modification of binding
affinity or cross-reactivity among HLA supertype family members, of
peptides of the invention can also be altered using analoging,
which is described in co-pending U.S. application Ser. No.
09/226,775 filed Jan. 6, 1999. In brief, the analoging strategy
utilizes the motifs or supermotifs that correlate with binding to
certain HLA molecules. Analog peptides can be created by
substituting amino acid residues at primary anchor, secondary
anchor, or at primary and secondary anchor positions. Generally,
analogs are made for peptides that already bear a motif or
supermotif. For a number of the motifs or supermotifs in accordance
with the invention, residues are defined which are deleterious to
binding to allele-specific HLA molecules or members of HLA
supertypes that bind the respective motif or supermotif (see, e.g.,
Rupert et al. Cell 74:929, 1993; Sidney, J. et al., Hu. Immunol.
45:79, 1996; and Sidney et al.; Sidney, et al., J. Immunol.
154:247, 1995). Accordingly, removal of such residues that are
detrimental to binding can be performed in accordance with the
present invention. For example, in the case of the A3 supertype,
when all peptides that have such deleterious residues are removed
from the population of peptides used in the analysis, the incidence
of cross-reactivity increased from 22% to 37% (see, e.g., Sidney,
J. et al., Hu. Immunol. 45:79, 1996).
[0123] Thus, one strategy to improve the cross-reactivity of
peptides within a given supermotif is simply to delete one or more
of the deleterious residues present within a peptide and substitute
a small "neutral" residue such as Ala (that may not influence T
cell recognition of the peptide). An enhanced likelihood of
cross-reactivity is expected if, together with elimination of
detrimental residues within a peptide, "preferred" residues
associated with high affinity binding to an allele-specific HLA
molecule or to multiple HLA molecules within a superfamily are
inserted.
[0124] In some embodiments, a T helper peptide can used in addition
to one of the peptides of the invention. One type of T helper
peptide is one that is recognized by T helper cells in the majority
of the population. This can be accomplished by selecting amino acid
sequences that bind to many, most, or all of the MHC class II
molecules. These are known as "loosely MHC-restricted" T helper
sequences. Examples of amino acid sequences that are loosely
MHC-restricted include sequences from antigens such as Tetanus
toxin at positions 830-843 (QYIKANSKFIGITE (SEQ ID NO: 1)),
Plasmodium falciparum circumsporozoite (CS) protein at positions
378-398 (DIEKKIAKMEKASSVFNVVNS (SEQ ID NO: 2)), and Streptococcus
18 kD protein at positions 1-16 (YGAVDSILGGVATYGAA (SEQ ID NO:
3)).
[0125] Alternatively, it is possible to prepare synthetic peptides
capable of stimulating T helper lymphocytes, in a loosely
MHC-restricted fashion, using amino acid sequences not found in
nature (see, e.g., PCT publication WO 95/07707). These synthetic
compounds, called Pan-DR-binding epitopes or PADRE.RTM. molecules
(Epimmune, San Diego, Calif.), are designed on the basis of their
binding activity to most HLA-DR (human MHC class II) molecules
(see, e.g., U.S. Ser. No. 08/121,101 (now abandoned) and related
U.S. Ser. No. 08/305,871 (now U.S. Pat. No. 5,736,142)). For
instance, a pan-DR-binding epitope peptide having the formula:
aKXVWANTLKAAa (SEQ ID NO: 4), where X is either cyclohexylalanine,
phenylalanine, or tyrosine, and "a" is either D-alanine or
L-alanine, has been found to bind to most HLA-DR alleles, and to
stimulate the response of T helper lymphocytes from most
individuals, regardless of their HLA type.
[0126] Particularly preferred immunogenic peptides and/or T helper
conjugates are linked by a spacer molecule. The spacer is typically
comprised of relatively small, neutral molecules, such as amino
acids or amino acid mimetics, which are substantially uncharged
under physiological conditions. The spacers are typically selected
from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino
acids or neutral polar amino acids. It will be understood that the
optionally present spacer need not be comprised of the same
residues and thus may be a hetero- or homo-oligomer. When present,
the spacer will usually be at least one or two residues, more
usually three to six residues. Alternatively, the HTL peptide may
be linked to the T helper peptide without a spacer.
[0127] The immunogenic peptide may be linked to the T helper
peptide either directly or via a spacer either at the amino or
carboxy terminus of the HTL peptide. The amino terminus of either
the immunogenic peptide or the T helper peptide may be acylated.
The T helper peptides used in the invention can be modified in the
same manner as HTL peptides. For instance, they may be modified to
include D-amino acids or be conjugated to other molecules such as
lipids, proteins, sugars and the like. Exemplary T helper peptides
include tetanus toxoid 830-843, influenza 307-319, malaria
circumsporozoite 382-398 and 378-389.
[0128] In some embodiments it may be desirable to include in the
pharmaceutical compositions of the invention at least one component
which primes HTL and CTL. Lipids have been identified as agents
capable of priming HTL and CTL in vivo against viral antigens. For
example, palmitic acid residues can be attached to the alpha and
epsilon amino groups of a Lys residue and then linked, e.g., via
one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser,
or the like, to an immunogenic peptide. The lipidated peptide can
then be injected directly in a micellar form, incorporated into a
liposome or emulsified in an adjuvant, e.g., incomplete Freund's
adjuvant. In a preferred embodiment a particularly effective
immunogen comprises palmitic acid attached to alpha and epsilon
amino groups of Lys, which is attached via linkage, e.g., Ser-Ser,
to the amino terminus of the immunogenic peptide. Also in a
preferred embodiment a particularly effective immunogen comprises
palmitic acid attached to alpha and epsilon amino groups of Lys,
which is attached via linkage, e.g., Ser-Ser, to the amino terminus
of a class I restricted peptide having T cell determinants, such as
those peptides described herein as well as other peptides which
have been identified as having such determinants
[0129] As another example of lipid priming of HTL and CTL
responses, E. coli lipoproteins, such as
tripalmitoyl-S-glycerylcysteinlyseryl-serine (P.sub.3CSS) can be
used to prime virus specific HTL CTL when covalently attached to an
appropriate peptide. See, Deres et al., Nature 342:561-564 (1989),
incorporated herein by reference. Peptides of the invention can be
coupled to P.sub.3CSS, for example, and the lipopeptide
administered to an individual to specifically prime a HTL response
to the target antigen. Further, as the induction of neutralizing
antibodies can also be primed with P.sub.3CSS conjugated to a
peptide which displays an appropriate epitope, the two compositions
can be combined to more effectively elicit both humoral and
cell-mediated responses to infection.
[0130] In addition, additional amino acids can be added to the
termini of a peptide to provide for ease of linking peptides one to
another, for coupling to a carrier support, or larger peptide, for
modifying the physical or chemical properties of the peptide or
oligopeptide, or the like. Amino acids such as tyrosine, cysteine,
lysine, glutamic or aspartic acid, or the like, can be introduced
at the C- or N-terminus of the peptide or oligopeptide.
Modification at the C terminus in some cases may alter binding
characteristics of the peptide. In addition, the peptide or
oligopeptide sequences can differ from the natural sequence by
being modified by terminal-NH2 acylation, e.g., by alkanoyl
(C.sub.1-C.sub.20) or thioglycolyl acetylation, terminal-carboxyl
amidation, e.g., ammonia, methylamine, etc. In some instances these
modifications may provide sites for linking to a support or other
molecule.
[0131] The peptides of the invention can be prepared in a wide
variety of ways. Because of their relatively short size, the
peptides can be synthesized in solution or on a solid support in
accordance with conventional techniques. Various automatic
synthesizers are commercially available and can be used in
accordance with known protocols. See, for example, Stewart and
Young, Solid Phase Peptide Synthesis, 2d. ed., Pierce Chemical Co.
(1984), supra.
[0132] Another aspect of the present invention is directed to
vaccines which comprise an immunogenically effective amount of one
or more peptides as described herein. Peptides may be introduced
into a host using a variety of delivery vehicles known to those of
skill in the art including PLG microspheres with entrapped peptides
and virus-like particles. Furthermore, epitopes may be introduced
as multiple antigen peptides (MAPs) (see e.g., Mora and Tam, J.
Immunol. 161:3616-23 (1998)), or as immunostimulating complexes
(ISCOMS) (see e.g., Hu et al. Clin. Exp. Immunol. 113:235-43
(1998)) as known in the art.
[0133] Vaccines that contain an immunogenically effective amount of
one or more peptides as described herein are a further embodiment
of the invention. The vaccines of the invention can be used both as
a prevantative or therapeutic. Once appropriately immunogenic
epitopes have been defined, they can be delivered by various means,
herein referred to as "vaccine" compositions. Such vaccine
compositions can include, for example, lipopeptides (e.g.,
Vitiello, A. et al., J: Clin. Invest. 95:341, 1995), peptide
compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG")
microspheres (see, e.g., Eldridge, et al., Molec. Immunol.
28:287-294, 1991: Alonso et al., Vaccine 12:299-306, 1994; Jones et
al., Vaccine 13:675-681, 1995), peptide compositions contained in
immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al.,
Nature 344:873-875, 1990; Hu et al., Clin Exp Immunol. 113:235-24:
1998), multiple antigen peptide systems (MAPs) (see e.g., Tam, J.
P., Proc. Nati. Acaa Sci. U.S.A. 85:5409-5413, 1988; Tam, J.P., J
Immunol. Methods 196:17-32, 1996), vir delivery vectors (Perkus, M.
E. et al., In: Concepts in vaccine development, Kaufmann H. E.,
ed., p. 379, 1996; Chakrabarti, S. et al., Nature 320:535,1986; Hu,
S. L. et al., Nature 320:537, 1986; Kieny, M.-P. et al., AIDS
Bio/Technology 4:790, 1986; Top, F. et al., J Infect. Dis. 124:148,
1971; Chanda, P. K. et al., Virology 175:535, 1990), particles of
viral or synthetic origin (e.g., Kofler, N. et al., J Immunol.
Methods. 192:2- 1996; Eldridge, J. H. et al., Sem. Bematol. 30:16,
1993; Fa10, L. D., Jr. et al., Nature Med. 7:649, 1995), adjuvants
(Warren, H. S., Vogel, F. R., and Chedid, L. A. Annu. Re Immunol.
4:369, 1986; Gupta, R. K. et al., Vaccine 11:293, 1993), liposomes
(Reddy, R et al., J. Immunol. 148:1585, 1992; Rock, K. L., Immunol.
Today 17:131, 1996), or, naked or particle absorbed cDNA (Ulmer, J.
B. et al., Science 259:1745, 1993; Robinsol H. L., Hunt, L. A., and
Webster, R. G., Vaccine 11:957, 1993; Shiver, J. W. et al., In:
Concepts in vaccine development, Kaufmann, S. H. E., ed., p. 423,
1996; Cease, K. B., and Berzofsky, J. A., Annu. Rev. Immunol.
12:923, 1994 and Eldridge, J. H. et al., Sem. Hematol. 30:16,
1993). Toxin-targeted delivery technologies, also known as receptor
mediated targeting, such as those of Avant Immunotherapeutics, Inc.
(Needham, Massachusetts) may also be used.
[0134] Vaccine compositions of the invention include nucleic
acid-mediated modalities. DNA or RNA encoding one or more of the
peptides of the invention can also be administered to a patient.
This approach is described, for instance, in Wolff et. al., Science
247: 1465 (1990) as well as U.S. Pat. Nos. 5,580,859; 5,589,466;
5,804,566;
[0135] 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more
detail below. Examples of DNA-based delivery technologies include
"naked DNA", facilitated (bupivicaine, polymers, peptide-mediated)
delivery, cationic lipid complexes, and particle-mediated ("gene
gun") or pressure-mediated delivery (see, e.g., U.S. Pat. No.
5,922,687).
[0136] For therapeutic or prophylactic immunization purposes, the
peptides of the invention can be expression vectors include
attenuated viral hosts, such as vaccinia or fowlpox. This approach
involves the use of vaccinia virus, for example, as a vector to
express nucleotide sequences that encode the pep tides of the
invention. Upon introduction into an acutely or chronically
infected host or into a non-infected host, the recombinant vaccinia
virus expresses the immunogenic peptide, and thereby elicits a host
CTL and/or HTL response. Vaccinia vectors and methods useful in
immunization protocols are described in, e.g., U.S. Pat. No.
4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG
vectors are described in Stover et al., Nature 351:456-460 (1991).
A wide variety of other vectors useful for therapeutic
administration or immunization of the peptides of the invention,
e.g. adeno and adeno-associated virus vectors, retroviral vectors,
Salmonella typhi vectors, detoxified anthrax toxin vectors, and the
like, will be apparent to those skilled in the art from the
description herein.
[0137] Furthermore, vaccines in accordance with the invention can
encompass one or more of the peptides of the invention.
Accordingly, a peptide can be present in a vaccine individually.
Alternatively, the peptide can be individually linked to its own
carrier; alternatively, the peptide can exist as a homopolymer
comprising multiple copies of the same peptide, or as a
heteropolymer of various peptides. Polymers have the advantage of
increased immunological reaction and, where different peptide
epitopes are used to make up the polymer, the additional ability to
induce antibodies and/or CTLs that react with different antigenic
determinants of the pathogenic organism or tumor-related peptide
targeted for an immune response. The composition may be a naturally
occurring region of an antigen or may be prepared, e.g.,
recombinantly or by chemical synthesis.
[0138] Carriers that can be used with vaccines of the invention are
well known in the art, and include, e.g., thyroglobulin, albumins
such as human serum albumin, tetanus toxoid, polyamino acids such
as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B
virus core protein, and the like. The vaccines can contain a
physiologically tolerable (i.e., acceptable) diluent such as water,
or saline, preferably phosphate buffered saline. The vaccines also
typically include an adjuvant. Adjuvants such as incomplete
Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum
are examples of materials well known in the art. Additionally, CTL
responses can be primed by conjugating peptides of the invention to
lipids, such as tripalmitoyl-S-glycerylcysteinlyseryl-serine
(P3CSS).
[0139] Upon immunization with a peptide composition in accordance
with the invention, via injection, aerosol, oral, transdermal,
transmucosal, intrapleural, intrathecal, or other suitable routes,
the immune system of the host responds to the vaccine by producing
large amounts of HTLs and/or CTLs specific for the desired antigen.
Consequently, the host becomes at least partially immune to later
infection, or at least partially resistant to developing an ongoing
chronic infection, or derives at least some therapeutic benefit
when the antigen was tumor-associated.
[0140] For therapeutic or immunization purposes, the peptides of
the invention can also be expressed by vectors. Examples of
expression vectors include attenuated viral hosts, such as vaccinia
or fowlpox. This approach involves the use of vaccinia virus as a
vector to express nucleotide sequences that encode the peptides of
the invention. Vaccinia vectors and methods useful in immunization
protocols are described in, e.g., U.S. Pat. No. 4,722,848. Another
vector is BCG (Bacille Calmette Guerin). BCG vectors are described
in Stover, et al. Nature 351:456-60 (1991). A wide variety of other
vectors useful for therapeutic administration or immunization of
the peptides of the invention, e.g., Salmonella typhi vectors,
retroviral vectors, adenoviral or adeno-associated viral vectors,
and the like will be apparent to those skilled in the art from the
description herein.
[0141] Alternatively, recombinant DNA technology may be employed
wherein a nucleotide sequence which encodes an immunogenic peptide
of interest is inserted into an expression vector, transformed or
transfected into an appropriate host cell and cultivated under
conditions suitable for expression. These procedures are generally
known in the art, as described generally in Sambrook et al.,
Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press,
Cold Spring Harbor, N.Y. (1982) (also 1989), which is incorporated
herein by reference. Thus, fusion proteins which comprise one or
more peptide sequences of the invention can be used to present the
appropriate T cell epitope. For example, a coding sequence encoding
a peptide of the invention can be provided with appropriate linkers
and ligated into expression vectors commonly available in the art,
and the vectors used to transform suitable hosts to produce the
desired fusion protein. A number of such vectors and suitable host
systems are now available. Expression constructs, i.e., minigenes
are described in greater detail in the sections below. Such
methodologies are also used to present at least one peptide of the
invention along with a substance which is not a peptide of the
invention.
[0142] As the coding sequence for peptides of the length
contemplated herein can be synthesized by chemical techniques, for
example, using the phosphotriester method of Matteucci et al., J.
Am. Chem. Soc. 103:3185 (1981), with modification can be made
simply by substituting the appropriate base(s) for those encoding
the native peptide sequence. The coding sequence can then be
provided with appropriate linkers and ligated into expression
vectors commonly available in the art, and the vectors used to
transform suitable hosts to produce the desired fusion protein. A
number of such vectors and suitable host systems are now available.
For expression of the fusion proteins, the coding sequence will be
provided with operably linked start and stop codons, promoter and
terminator regions and usually a replication system to provide an
expression vector for expression in the desired cellular host. For
example, promoter sequences compatible with bacterial hosts are
provided in plasmids containing convenient restriction sites for
insertion of the desired coding sequence. The resulting expression
vectors are transformed into suitable bacterial hosts. Of course,
yeast or mammalian cell hosts may also be used, employing suitable
vectors and control sequences.
[0143] The peptides of the present invention and pharmaceutical and
vaccine compositions thereof are useful for administration to
mammals, particularly humans, to treat and/or prevent cancer.
[0144] In therapeutic applications, compositions are administered
to a patient in an amount sufficient to elicit an effective HTL
response to the tumor antigen and to cure or at least partially
arrest symptoms and/or complications. An amount adequate to
accomplish this is defined as "therapeutically effective dose" or
"unit dose." Amounts effective for this use will depend on, e.g.,
the peptide composition, the manner of administration, the stage
and severity of the disease being treated, the weight and general
state of health of the patient, and the judgment of the prescribing
physician, but generally range for the initial immunization (that
is for therapeutic or prophylactic administration) from about 1.0
.mu.g to about 5000 .mu.g of peptide for a 70 kg patient, followed
by boosting dosages of from about 1.0 .mu.g to about 1000 .mu.g of
peptide pursuant to a boosting regimen over weeks to months
depending upon the patient's response and condition by measuring
specific CTL activity in the patient's blood. In alternative
embodiments, generally for humans the dose range for the initial
immunization (that is for therapeutic or prophylactic
administration) is from about 1.0 .mu.g to about 20,000 .mu.g of
peptide for a 70 kg patient, preferably, 100 .mu.g-, 150 .mu.g-,
200 .mu.g-, 250 .mu.g-, 300 .mu.g-, 400 .mu.g-, or 500 .mu.g-20,000
.mu.g, followed by boosting dosages in the same dose range pursuant
to a boosting regimen over weeks to months depending upon the
patient's response and condition by measuring specific HTL activity
in the patient's blood. In embodiments where recombinant nucleic
acid administration is used, the administered material is titrated
to achieve the appropriate therapeutic response.
[0145] It must be kept in mind that the peptides and compositions
of the present invention may generally be employed in serious
disease states, that is, life-threatening or potentially life
threatening situations. In such cases, in view of the minimization
of extraneous substances and the relative nontoxic nature of the
peptides, it is possible and may be felt desirable by the treating
physician to administer substantial excesses of these peptide
compositions.
[0146] For therapeutic use, administration should begin at the
first sign of tumors or shortly after diagnosis. This is followed
by boosting doses until at least symptoms are substantially abated
and for a period thereafter.
[0147] Treatment of an affected individual with the compositions of
the invention may hasten resolution of the infection in acutely
infected individuals. For those individuals susceptible (or
predisposed) to developing cancer the compositions are particularly
useful in methods for preventing the evolution of cancer.
[0148] The pharmaceutical compositions for therapeutic treatment
are intended for parenteral, topical, oral or local administration.
Preferably, the pharmaceutical compositions are administered
parenterally, e.g., intravenously, subcutaneously, intradermally,
or intramuscularly. Thus, the invention provides compositions for
parenteral administration which comprise a solution of the
immunogenic peptides dissolved or suspended in an acceptable
carrier, preferably an aqueous carrier. A variety of aqueous
carriers may be used, e.g., water, buffered water, 0.8% saline,
0.3% glycine, hyaluronic acid and the like. These compositions may
be sterilized by conventional, well known sterilization techniques,
or may be sterile filtered. The resulting aqueous solutions may be
packaged for use as is, or lyophilized, the lyophilized preparation
being combined with a sterile solution prior to administration. The
compositions may contain pharmaceutically acceptable auxiliary
substances as required to approximate physiological conditions,
such as pH adjusting and buffering agents, tonicity adjusting
agents, wetting agents and the like, for example, sodium acetate,
sodium lactate, sodium chloride, potassium chloride, calcium
chloride, sorbitan monolaurate, triethanolamine oleate, etc.
[0149] A pharmaceutical composition of the invention may comprise
one or more T cell stimulatory peptides of the invention. For
example, a pharmaceutical composition may comprise 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30 or more T cell stimulatory peptides of
the invention. Moreover, a pharmaceutical composition of the
invention may comprise one or more T cell stimulatory peptides of
the invention in combination with one or more other T cell
stimulatory peptides. The concentration of each unique T cell
stimulatory peptide of the invention in the pharmaceutical
formulations can vary widely, e.g., from less than about 0.001%,
about 0.002%, about 0.003%, about 0.004%, about 0.005%, about
0.006%, 0.007%, 0.008%, 0.009%, about 0.01%, about 0.02%, about
0.025%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about
0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about
0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%,
about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about
1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%,
about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about
8%, about 9%, about 10%, about 20%, to about 50% or more by weight,
and will be selected primarily by fluid volumes, viscosities, etc.,
in accordance with the particular mode of administration selected.
In a preferred embodiment, the concentration of each unique T cell
stimulatory peptide of the invention in the pharmaceutical
formulations is about 0.001%, about 0.002%, about 0.003%, about
0.004%, about 0.005%, about 0.006%, 0.007%, 0.008%, 0.009%, about
0.01%, about 0.02%, about 0.025%, about 0.03%, about 0.04%, about
0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about
0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%,
about 0.7%, about 0.8%, about 0.9%, about 1% by weight. In a more
preferred embodiment, the concentration of each unique T cell
stimulatory peptide of the invention in the pharmaceutical
formulations is about 0.01%, about 0.02%, about 0.025%, about
0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about
0.08%, about 0.09%, about 0.1% by weight.
[0150] The concentration of HTL stimulatory peptides of the
invention in the pharmaceutical formulations can vary widely, i.e.,
from less than about 0.1%, usually at or at least about 2% to as
much as 20% to 50% or more by weight, and will be selected
primarily by fluid volumes, viscosities, etc., in accordance with
the particular mode of administration selected. A human unit dose
form of the peptide composition is typically included in a
pharmaceutical composition that comprises a human unit dose of an
acceptable carrier, preferably an aqueous carrier, and is
administered in a volume of fluid that is known by those of skill
in the art to be used for administration of such compositions to
humans.
[0151] The peptides of the invention may also be administered via
liposomes, which serve to target the peptides to a particular
tissue, such as lymphoid tissue, or targeted selectively to
infected cells, as well as increase the half-life of the peptide
composition.
[0152] Liposomes include emulsions, foams, micelles, insoluble
monolayers, liquid crystals, phospholipid dispersions, lamellar
layers and the like. In these preparations the peptide to be
delivered is incorporated as part of a liposome, alone or in
conjunction with a molecule which binds to, e.g., a receptor
prevalent among lymphoid cells, such as monoclonal antibodies which
bind to the CD45 antigen, or with other therapeutic or immunogenic
compositions. Thus, liposomes either filled or decorated with a
desired peptide of the invention can be directed to the site of
lymphoid cells, where the liposomes then deliver the selected
therapeutic/immunogenic peptide compositions. Liposomes for use in
the invention are formed from standard vesicle-forming lipids,
which generally include neutral and negatively charged
phospholipids and a sterol, such as cholesterol. The selection of
lipids is generally guided by consideration of, e.g., liposome
size, acid lability and stability of the liposomes in the blood
stream. A variety of methods are available for preparing liposomes,
as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng.
9:467 (1980), U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and
5,019,369, incorporated herein by reference.
[0153] For targeting to the immune cells, a ligand to be
incorporated into the liposome can include, e.g., antibodies or
fragments thereof specific for cell surface determinants of the
desired immune system cells. A liposome suspension containing a
peptide may be administered intravenously, locally, topically, etc.
in a dose which varies according to, inter alia, the manner of
administration, the peptide being delivered, and the stage of the
disease being treated.
[0154] For solid compositions, conventional nontoxic solid carriers
may be used which include, for example, pharmaceutical grades of
mannitol, lactose, starch, magnesium stearate, sodium saccharin,
talcum, cellulose, glucose, sucrose, magnesium carbonate, and the
like. For oral administration, a pharmaceutically acceptable
nontoxic composition is formed by incorporating any of the normally
employed excipients, such as those carriers previously listed, and
generally 10-95% of active ingredient, that is, one or more
peptides of the invention, and more preferably at a concentration
of 25%-75%.
[0155] For aerosol administration, the immunogenic peptides are
preferably supplied in finely divided form along with a surfactant
and propellant. Typical percentages of peptides are 0.01%-20% by
weight, preferably 1%-10%. The surfactant must, of course, be
nontoxic, and preferably soluble in the propellant. Representative
of such agents are the esters or partial esters of fatty acids
containing from 6 to 22 carbon atoms, such as caproic, octanoic,
lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic
acids with an aliphatic polyhydric alcohol or its cyclic anhydride.
Mixed esters, such as mixed or natural glycerides may be employed.
The surfactant may constitute 0.1%-20% by weight of the
composition, preferably 0.25-5%. The balance of the composition is
ordinarily propellant. A carrier can also be included, as desired,
as with, e.g., lecithin for intranasal delivery.
[0156] In another aspect the present invention is directed to
vaccines which contain as an active ingredient an immunogenically
effective amount of an immunogenic peptide as described herein. The
peptide(s) may be introduced into a host, including humans, linked
to its own carrier or as a homopolymer or heteropolymer of active
peptide units. Such a polymer has the advantage of increased
immunological reaction and, where different peptides are used to
make up the polymer, the additional ability to induce antibodies
and/or CTLs that react with different antigenic determinants of
tumor cells. Useful carriers are well known in the art, and
include, e.g., thyroglobulin, albumins such as human serum albumin,
tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid),
influenza, hepatitis B virus core protein, hepatitis B virus
recombinant vaccine and the like. The vaccines can also contain a
physiologically tolerable (acceptable) diluent such as water,
phosphate buffered saline, or saline, and further typically include
an adjuvant. Adjuvants such as incomplete Freund's adjuvant,
aluminum phosphate, aluminum hydroxide, or alum are materials well
known in the art. Upon immunization with a peptide composition as
described herein, via injection, aerosol, oral, transdermal or
other route, the immune system of the host responds to the vaccine
by producing large amounts of HTLs specific for the desired
antigen, and the host becomes at least partially immune to later
infection, or resistant to developing chronic infection.
[0157] The peptides of the present invention and pharmaceutical and
vaccine compositions of the invention are useful for administration
to mammals, particularly humans, to treat and/or prevent cancer.
Vaccine compositions containing the peptides of the invention are
administered to a patient susceptible to or otherwise at risk of
cancer to elicit an immune response against the antigen and thus
enhance the patient's own immune response capabilities. Such an
amount is defined to be an "immunogenically effective dose." In
this use, the precise amounts again depend on the patient's state
of health and weight, the mode of administration, the nature of the
formulation, etc., but generally range from about 1.0 .mu.g to
about 5000 .mu.g per 70 kilogram patient, more commonly from about
10 .mu.g to about 500 .mu.g mg per 70 kg of body weight.
[0158] As noted herein, the peptides of the invention induce HTL
immune responses when contacted with a HTL specific to an epitope
comprised by the peptide. The manner in which the peptide is
contacted with the HTL is not critical to the invention. For
instance, the peptide can be contacted with the HTL either in vivo
or in vitro. If the contacting occurs in vivo, the peptide itself
can be administered to the patient or other vehicles, e.g., DNA
vectors encoding one or more peptide, viral vectors encoding the
peptide(s), liposomes and the like, can be used, as described
herein.
[0159] For therapeutic or immunization purposes, nucleic acids
encoding one or more of the peptides of the invention can also be
administered to the patient. A number of methods are conveniently
used to deliver the nucleic acids to the patient. For instance, the
nucleic acid can be delivered directly, as "naked DNA". This
approach is described, for instance, in Wolff et. al., Science 247:
1465-68 (1990) as well as U.S. Pat. Nos. 5,580,859 and 5,589,466.
The nucleic acids can also be administered using ballistic delivery
as described, for instance, in U.S. Pat. No. 5,204,253. Particles
comprised solely of DNA can be administered. Alternatively, DNA can
be adhered to particles, such as gold particles.
[0160] The nucleic acids can also be delivered complexed to
cationic compounds, such as cationic lipids. Lipid-mediated gene
delivery methods are described, for instance, in WO 96/18372; WO
93/24640; Mannino and Gould-Fogerite (1988) BioTechniques 6(7):
682-691; Rose U.S. Pat No. 5,279,833; WO 91/06309; and Feigner et
a/. (1987) Proc. Natl. Acad. Sci. USA 84: 7413-14.
[0161] Nucleic acids encoding one or more of the peptides of the
invention can also be administered to the patient. This approach is
described, for instance, in Wolff, et. al., Science, 247:1465-68
(1990) as well as U.S. Pat. Nos. 5,580,859 and 5,589,466.
[0162] A preferred means of administering nucleic acids encoding
the peptides of the invention uses minigene constructs encoding
multiple epitopes of the invention. To create a DNA sequence
encoding the selected HTL epitopes (minigene) for expression in
human cells, the amino acid sequences of the epitopes are reverse
translated. A human codon usage table is used to guide the codon
choice for each amino acid. These epitope-encoding DNA sequences
are directly adjoined, creating a continuous polypeptide sequence.
To optimize expression and/or immunogenicity, additional elements
can be incorporated into the minigene design. Examples of amino
acid sequence that could be reverse translated and included in the
minigene sequence include: a leader (signal) sequence, and an
endoplasmic reticulum retention signal. In addition, MHC
presentation of HTL epitopes may be improved by including synthetic
(e.g. poly-alanine) or naturally-occurring flanking sequences
adjacent to the HTL epitopes.
[0163] The minigene sequence is converted to DNA by assembling
oligonucleotides that encode the plus and minus strands of the
minigene. Overlapping oligonucleotides (30-100 bases long) are
synthesized, phosphorylated, purified and annealed under
appropriate conditions using well known techniques. The ends of the
oligonucleotides are joined using T4 DNA ligase. This synthetic
minigene, encoding the HTL epitope polypeptide, can then cloned
into a desired expression vector.
[0164] Standard regulatory sequences well known to those of skill
in the art are included in the vector to ensure expression in the
target cells. Several vector elements are required: a promoter with
a down-stream cloning site for minigene insertion; a
polyadenylation signal for efficient transcription termination; an
E. coli origin of replication; and an E. coli selectable marker
(e.g. ampicillin or kanamycin resistance). Numerous promoters can
be used for this purpose, e.g., the human cytomegalovirus (hCMV)
promoter. See, U.S. Pat. Nos. 5,580,859 and 5,589,466 for other
suitable promoter sequences.
[0165] Additional vector modifications may be desired to optimize
minigene expression and immunogenicity. In some cases, introns are
required for efficient gene expression, and one or more synthetic
or naturally-occurring introns could be incorporated into the
transcribed region of the minigene. The inclusion of mRNA
stabilization sequences can also be considered for increasing
minigene expression. It has recently been proposed that
immunostimulatory sequences (ISSs or CpGs) play a role in the
immunogenicity of DNA vaccines. These sequences could be included
in the vector, outside the minigene coding sequence, if found to
enhance immunogenicity.
[0166] In some embodiments, a bicistronic expression vector, to
allow production of the minigene-encoded epitopes and a second
protein included to enhance or decrease immunogenicity can be used.
Examples of proteins or polypeptides that could beneficially
enhance the immune response if co-expressed include cytokines
(e.g., IL2, IL12, GM-CSF), cytokine-inducing molecules (e.g., LeIF)
or costimulatory molecules. Helper (HTL) epitopes could be joined
to intracellular targeting signals and expressed separately from
the CTL epitopes. This would allow direction of the HTL epitopes to
a cell compartment different than the CTL epitopes. If required,
this could facilitate more efficient entry of HTL epitopes into the
MHC class II pathway, thereby improving CTL induction. In contrast
to CTL induction, specifically decreasing the immune response by
co-expression of immunosuppressive molecules (e.g. TGF-.beta.) may
be beneficial in certain diseases.
[0167] Once an expression vector is selected, the minigene is
cloned into the polylinker region downstream of the promoter. This
plasmid is transformed into an appropriate E. coil strain, and DNA
is prepared using standard techniques. The orientation and DNA
sequence of the minigene, as well as all other elements included in
the vector, are confirmed using restriction mapping and DNA
sequence analysis. Bacterial cells harboring the correct plasmid
can be stored as a master cell bank and a working cell bank.
[0168] Therapeutic quantities of plasmid DNA are produced by
fermentation in E. coli, followed by purification. Aliquots from
the working cell bank are used to inoculate fermentation medium
(such as Terrific Broth), and grown to saturation in shaker flasks
or a bioreactor according to well known techniques. Plasmid DNA can
be purified using standard bioseparation technologies such as solid
phase anion-exchange resins supplied by Quiagen. If required,
supercoiled DNA can be isolated from the open circular and linear
forms using gel electrophoresis or other methods.
[0169] Purified plasmid DNA can be prepared for injection using a
variety of formulations. The simplest of these is reconstitution of
lyophilized DNA in sterile phosphate-buffer saline (PBS). A variety
of methods have been described, and new techniques may become
available. As noted above, nucleic acids are conveniently
formulated with cationic lipids. In addition, glycolipids,
fusogenic liposomes, peptides and compounds referred to
collectively as protective, interactive, non-condensing (PINC)
could also be complexed to purified plasmid DNA to influence
variables such as stability, intramuscular dispersion, or
trafficking to specific organs or cell types.
[0170] The nucleic acids can also be administered using ballistic
delivery as described, for instance, in U.S. Pat. No. 5,204,253.
Particles comprised solely of DNA can be administered.
Alternatively, DNA can be adhered to particles, such as gold
particles.
[0171] In vivo immunogenicity is a second approach for functional
testing of minigene DNA formulations. Transgenic mice expressing
appropriate human MHC molecules are immunized with the DNA product.
The dose and route of administration are formulation dependent
(e.g. IM for DNA in PBS, IP for lipid-complexed DNA). Twenty-one
days after immunization, splenocytes are harvested and restimulated
for 1 week in the presence of peptides encoding each epitope being
tested.
[0172] An embodiment of a vaccine composition in accordance with
the invention comprises ex vivo administration of a cocktail of
epitope-bearing peptides to PBMC, or isolated DC therefrom, from
the patient's blood. After pulsing the DC with peptides and prior
to reinfusion into patients, the DC are washed to remove unbound
peptides. In this embodiment, a vaccine comprises peptide-pulsed
DCs which present the pulsed peptide epitopes in HLA molecules on
their surfaces.
[0173] Dendritic cells can also be transfected, e.g., with a
minigene comprising nucleic acid sequences encoding the epitopes in
accordance with the invention, in order to elicit immune responses.
Vaccine compositions can be created in vitro, following dendritic
cell mobilization and harvesting, whereby loading of dendritic
cells occurs in vitro.
[0174] Transgenic animals of appropriate haplotypes may
additionally provide a useful tool in optimizing the in vivo
immunogenicity of minigene DNA. In addition, animals such as
monkeys having conserved HLA molecules with cross reactivity to CTL
epitopes recognized by human MHC molecules can be used to determine
human immunogenicity of CTL epitopes (Bertoni, et al., J. Immunol.
161:4447-4455 (1998)).
[0175] Such in vivo studies are required to address the variables
crucial for vaccine development, which are not easily evaluated by
in vitro assays, such as route of administration, vaccine
formulation, tissue biodistribution, and involvement of primary and
secondary lymphoid organs. Because of their simplicity and
flexibility, HLA transgenic mice represent an attractive
alternative, at least for initial vaccine development studies,
compared to more cumbersome and expensive studies in higher animal
species, such as nonhuman primates.
[0176] Antigenic peptides are used to elicit a HTL response ex
vivo, as well. The resulting HTL cells, can be used to treat tumors
in patients that do not respond to other conventional forms of
therapy, or will not respond to a therapeutic vaccine peptide or
nucleic acid in accordance with the invention. Ex vivo HTL
responses to a particular antigen are induced by incubating in
tissue culture the patient's (HTLp), or genetically compatible, HTL
precursor cells together with a source of antigen-presenting cells
(APC), such as dendritic cells, and the appropriate immunogenic
peptide. After an appropriate incubation time (typically about 7-28
days (1-4 weeks)), in which the precursor cells are activated and
matured and expanded into effector cells, the cells are infused
back into the patient, where they will destroy their specific
target cell (an infected cell or a tumor cell). Transfected
dendritic cells may also be used as antigen presenting cells. In
order to optimize the in vitro conditions for the generation of
specific helper T cells, the culture of stimulator cells is
maintained in an appropriate serum-free medium.
[0177] The peptides may also find use as diagnostic reagents. For
example, a peptide of the invention may be used to determine the
susceptibility of a particular individual to a treatment regimen
which employs the peptide or related peptides, and thus may be
helpful in modifying an existing treatment protocol or in
determining a prognosis for an affected individual. In addition,
the peptides may also be used to predict which individuals will be
at substantial risk for developing chronic infection.
[0178] For example, a peptide of the invention may be used in a
tetramer staining assay to assess peripheral blood mononuclear
cells for the presence of antigen-specific CTLs following exposure
to a pathogen or immunogen. The HLA-tetrameric complex is used to
directly visualize antigen-specific CTLs (see, e.g., Ogg, et al.
Science 279:2103-2106, 1998; and Altman, et al. Science 174:94-96,
1996) and determine the frequency of the antigen-specific CTL
population in a sample of peripheral blood mononuclear cells. A
tetramer reagent using a peptide of the invention may be generated
as follows: A peptide that binds to an allele-specific HLA molecule
or supertype molecule is refolded in the presence of the
corresponding HLA heavy chain and 132-microglobulin to generate a
trimolecular complex. The complex is biotinylated at the carboxyl
terminal end of the heavy chain at a site that was previously
engineered into the protein. Tetramer formation is then induced by
the addition of streptavidin. By means of fluorescently labeled
streptavidin, the tetramer can be used to stain antigen-specific
cells. The cells may then be identified, for example, by flow
cytometry. Such an analysis may be used for diagnostic or
prognostic purposes. In addition, the peptides may also be used to
predict which individuals will be at substantial risk for
developing chronic infection.
[0179] All publications, patents, and patent applications cited in
this specification are herein incorporated by reference as if each
individual publication, patent or patent application were
specifically and individually indicated to be incorporated by
reference. Although the foregoing invention has been described in
some detail by way of illustration and example for purposes of
clarity of understanding, it will be readily apparent to one of
ordinary skill in the art in light of the teachings of this
invention that certain changes and modifications may be made
thereto without departing from the spirit or scope of the appended
claims.
EXAMPLES
Materials and Methods
[0180] The following materials and methods apply generally to all
the examples disclosed herein. Specific materials and methods are
disclosed in each example, as necessary.
[0181] Reagents: Anti-IFN-.gamma. and biotinylated anti-IFN-.gamma.
were obtained from Mabtech (Sweden). Phorbol myristate acetate
(PMA), human serum albumin (HSA), polyclonal human IgG, tetanus
toxin (TT), and ionomycin were from Sigma (St. Louis, Mo., USA).
Goat anti-human horseradish peroxidase (HRP)-conjugated antibody
was obtained from Santa Cruz Biotechnology (Santa Cruz, Calif.).
Hank's balanced salts solution (HBSS), RPMI-1640 and
phosphate-buffered saline were from Cellgro (Hernden, Va., USA).
Ficoll-Paque was from Amersham Biosciences (Uppsala, Sweden). All
peptides were synthesized by either the Mayo Clinic Protein
Chemistry and Proteomics Core or by Epimmune, Inc. (San Diego,
Calif.) and purified to >95% homogeneity by reverse-phase HPLC
as previously described (Dzuris J L, Sidney J, Appella E, Chesnut R
W, Watkins D I, Sette A. Conserved MHC class I peptide binding
motif between humans and rhesus macaques. J Immunol 2000;164:
283-91). Purity of peptides was determined with reverse-phase HPLC
and amino acid analysis, sequencing, and/or mass spectrometry.
Lyophilized peptides were resuspended at 20 mg/ml in 100% DMSO and
then diluted to required concentrations in PBS.
[0182] Epitope Prediction: The prediction program used, PIC
(Predicted IC50), is a modified linear coefficient, or matrix-based
method for predicting peptides with HLA-DR binding capacity. PIC is
predicated on the assumption that each residue along a peptide
molecule can independently contribute to binding affinity (Sette A,
et al. Proc Natl Acad Sci U S A 1989;86: 3296-300; Sette A, et al.
J Immunol 1989;142: 35-40). The algorithm yields a predicted IC50
value (designated as PIC) for the corresponding input sequence.
Lower PIC values indicate a higher probability of binding to HLA.
The program analyzes 15 amino acid long sequences offset by 3
residues encompassing the entire protein.
[0183] Peripheral Blood Mononuclear Cell Preparation (PBMC): PBMC
were isolated from blood as described (Disis M L, et al. Clin
Cancer Res 1999;5: 1289-97), and cryopreserved in liquid nitrogen
(20.times.106/ml cells) in freezing media (RPMI with 12.5% HSA,
penicillin, streptomycin and 2 mM glutamine) (Disis ML et al. J
Immunol Methods 2005.).
[0184] HLA-DR purification. Fifteen distinct HLA-DR molecules were
used in quantitative assays to measure the binding of peptides to
solubilized HLA-DR molecules. These HLA-DR molecules were chosen to
allow balanced population coverage: DRB1*0101, DRB1*1501,
DRB1*0301, DRB1*0401, DRB1*0404, DRB1*1101, DRBS*0101, DRB4*0101,
DRB3*0101, DRB1*0701, DRB1*0405, DRB1*0802, DRB1*0901, DRB1*1201,
and DRB1*1302 (24). MHC molecules utilized were purified from EBV
transformed homozygous cell lines or single MHC allele transfected
721.221, C1R, or fibroblast lines. The cell lines were maintained
by culture in RPMI-1640 medium supplemented with 2 mM L-glutamine,
100 U (100 .mu.g/ml) penicillin-streptomycin solution, and 10%
heat-inactivated FCS. HLA-DR molecules were purified using
antibody-based affinity chromatography from cell lysates prepared
in 50 mM Tris-HCL, pH 8.5, containing 1% (v/v) NP-40, 150 mM NaCl,
5 mM EDTA, and 2 mM PMSF. Briefly, columns of inactivated Sepharose
CL4B and Protein A Sepharose were used as pre-columns. HLA-DR
molecules were captured by passage of lysates over LB3.1 monoclonal
antibody (anti-HLA-DRA) columns. Antibody columns were washed with
10 mM Tris-HCL, pH8.0 with 1% (v/v) NP-40, followed by PBS
containing 0.4% (w/v) n-octylglucoside. MHC molecules were then
eluted with 50 mM diethylamine in 0.15 M NaCl containing 0.4% (w/v)
n-octylglucoside, pH 11.5. The pH was reduced to 8.0 and the
eluates were concentrated by centrifugation in Centriprep 30
concentrators at 2000 rpm (Amicon, Beverly, Mass.).
[0185] HLA-DR binding assays: Radioligand binding inhibition assays
were used to measure the binding of peptides to soluble HLA-DR
molecules based on the inhibition of binding of a radiolabeled
standard peptide as described previously (Sidney J, Southwood S,
Oseroff C, del Guercio M F, Grey H M, Sette A. Measurement of
MHC/peptide interactions by gel filtration. Curr Protocols Immunol
1998;18: 18.3.2-.3.9.). Briefly, 1-10 nM of radiolabeled peptide
was co-incubated for 2 days at either room temperature or
37.degree. C. with 1 .mu.M to 1 nM purified HLA-DR molecules in the
presence of a cocktail of protease inhibitors. Assays were
performed at various pH conditions, ranging from pH 4 to pH 7. The
final pH of assay mixtures is adjusted using citrate buffer as
described elsewhere (Sidney J, Curr Protocols Immunol 1998). After
incubation, the percentage of HLA-DR-bound radioactivity is
determined by capturing HLA-DR/peptide complexes on Optiplates
(Packard Instruments, Meriden, Conn.) coated with the LB3.1
antibody and determining bound counts per minute using the TopCount
microscintillation counter (Packard Instruments). The amount of
HLA-DR yielding 10-20% bound radioactivity is used in the
inhibition assays in which the concentration of peptide yielding
50% inhibition of the binding of the radiolabeled peptide was
calculated. Under the conditions used, the measured IC.sub.50
values are reasonable approximations of the true Kd values.
Competitor peptides are tested in 2-4 complete, independent
experiments, at concentrations ranging from 30 .mu.g/mL to 300
.mu.g/mL. As in previous studies, peptides with affinities for
specific HLA-DR molecules of 1000 nM or better are defined as
binders for the respective antigens.
[0186] Enzyme-linked immunosorbent spot assay. A 10-day ELlspot for
detecting low-frequency T cells was used to determine reactivity to
the tumor antigen peptides (Table 1) as described (Knutson K L et
al. J Clin Onc 2006;24: 4254-61). A positive response to a peptide
was defined as a frequency that was significantly (p<0.05,
two-tailed t test) greater than the mean of control no-antigen
wells and detectable (i.e., >1:100,000). PMA/Ionomycin and the
CEF pool were used as positive non-tumor related controls as
previously described (Knutson, 2006).
[0187] ELISA. ELISAs were done as previously described (Knutson,
2006). Briefly, 96-well plates were coated with 1 .mu.g/ml IGFBP-2
protein, 200 ng/ml tetanus toxin or 1 .mu.g/ml BSA. Human IgG was
added at a concentration range of 200 to 0.2 ng/ml to some wells
for standard curve generation. After washing and blocking, human
sera were added to the plate at a 1:40 dilution in triplicate and
plates were incubated for 2 hr at RT. After washing, 100 .mu.L/well
of HRP (Santa Cruz Biotechnology) was diluted 1:2000 and incubated
for 1 hr at RT. After a final wash, each well was incubated with
100 .mu.L (tetramethylbenzadine) TMB substrate (BD Bioscience).
Color development was stopped with diluted HCL and absorbance was
read at 450 nm on a plate reader.
[0188] The following examples are provided by way of illustration
only and not by way of limitation. Those of skill in the art will
readily recognize a variety of non-critical parameters that could
be changed or modified to yield essentially similar results.
Example 1
[0189] Identification of Conserved HLA Class II- Restricted
Peptides Derived from Tumor Associated Antigens Using Established
Motif Search Algorithms
[0190] To identify epitopes useful for vaccine design, a
multidisciplinary approach was used based initially on amino acid
motif searching of tumor associated antigen sequences to identify
potential HLA Class II motifs (see Table I). This was followed by
high throughput synthetic peptide binding assays using purified HLA
molecules to determine affinity and breadth of epitope peptide
binding.
[0191] Algorithm motif searches: Motif search algorithms were
validated for the most common HLA Class II alleles and were focused
on the HLA DRB1*0101, DRB1*1501, DRB1*0301, DRB1*0401, DRB1*0404,
DRB1*1101, DRB5*0101, DRB4*0101, DRB3*0101, DRB1*0701, DRB1*0405,
DRB1*0802, DRB1*0901, DRB1*1201, and DRB1*1302 supertypes in order
to attain virtually 100% population coverage. The selected tumor
associated antigen sequences were scanned for motif positive amino
acid sequences using the motif definitions.
[0192] A total of about 150 Class II-restricted peptide sequences
were identified that were specific for various DR supertypes (see
Table I). Table I lists for each identified DR antigen peptide, the
IC.sub.50 (nM) for each purified HLA.
Example 2
[0193] Identification of HTL Epitopes for Tumor Vaccine Inclusion
Of the peptides listed in Table I, those peptides that bound to at
least 4 different HLA with an IC.sub.50 of less than 1000 nM were
identified and are shown in Table II. The peptide sequences of
Table II were further evaluated for their binding capacity to
purified MHC molecules. FIGS. 1 through 4 show those peptides of
Table II which were immunogenic (shown in a circle). These HTL
peptides are candidates for inclusion into a tumor vaccine.
[0194] Using predictive algorithms discussed above, candidate
HLA-DR1-binding epitopes were identified. Binding assays targeting
15 different HLA-DR molecules revealed that 10 of the epitopes were
indiscriminate, binding (IC.sub.50<1000 nM) to at least four
different HLA-DR variants. An interferon-gamma ELIspot assay was
used to assess immunity to the indiscriminate binding peptides in
48 patients with either breast or ovarian cancer and 18 healthy
controls. The results showed that elevated T cell immunity in
patients was detected to several peptides (FIGS. 1-4).
[0195] Healthy donor and patient samples were obtained. Patients
were free from active treatment for at least 30 days when blood
(200 ml) was collected. For the T cell studies, the mean
(.+-.s.e.m) ages of the healthy donors and patients were 42.+-.11
and 55.+-.2 years, respectively (p<0.0001). Due to sera
unavailability, not all of the controls used in the T cell studies
were examined for tumor associated antigen antibodies in their
sera. However, additional control and patient sera were available
for antibody assessment. Additional healthy donor sera was obtained
from Bioreclamation (Hicksville, N.Y.).
[0196] Using an ELlspot assay with a limit of detection of
approximately 1:100,000 antigen-specific T cells per million PBMC,
patient-derived PBMC were screened for reactivity against all of
the HLA-DR binding peptides. The immunogenicity data of several
peptides is shown in FIGS. 1-4.
Example 3
Design and Development of Multi-Epitope Vaccines
[0197] Peptides that bound to at least 4 different HLA subtypes as
described above, and were shown to be immunogenic, as shown in
FIGS. 1-4, were selected for inclusion in a multi-epitope vaccine.
Table III shows the percent of patients that demonstrated positive
responses and the binding patterns to specific HLA subtypes of
eight vaccine candidates.
[0198] These example and equivalents thereof will become more
apparent to those skilled in the art in light of the present
disclosure and the accompanying claims. It should be understood,
however, that the examples are designed for the purpose of
illustration only and not limiting of the scope of the invention in
any way.
TABLE-US-00002 TABLE I HLA-DR binding affinity of
Breast/Ovarian-derived peptides IC.sub.50 nM purified HLA DRB1 DRB1
DRB1 DRB1 DRB1 DRB1 Peptide Sequence Source Protein Position *0101
*0301 *0401 *0404 *0405 *0701 9019.0104 RWCIPWQRLLLTASL CEA.10 CEA
10 1467 7860 426 193 221 107 9019.0105 LLTFWNPPTTAKLTI CEA.24 CEA
24 6.9 16,313 273 52 258 3.7 9019.0106 TAKLTIESTPFNVAE CEA.33 CEA
33 72 613 106 41 383 70 9019.0107 EVLLLVHNLPQHLFG CEA.50 CEA 50 2.7
830 3.4 1.7 30 5.4 9019.0108 YSWYKGERVDGNRQI CEA.65 CEA 65 511 --
34 585 360 866 9019.0109 NRQIIGYVIGTQQAT CEA.76 CEA 76 216 -- 108
1.5 129 46 9019.0110 QYVIGTQQATPGPAY CEA.81 CEA 81 21 31 34 4210
1705 9019.0111 GPAYSGREIIYPNAS CEA.92 CEA 92 9435 12,989 5252
9019.0112 GREIIYPNASLLIQN CEA.97 CEA 97 62 433 251 88 550 29
9019.0113 DIGFYTLHVIKSDLV CEA.116 CEA 116 64 984 84 260 95 23
9019.0114 FLTLHVIKSDLVNEE CEA.119 CEA 119 101 80 184 169 41 56
9019.0005 LHVIKSDLVNEEATG CEA.122 CEA 122 891 46 214 103 37 3893
9019.0115 KSDLVNEEATGQFRV CEA.126 CEA 126 13,600 2530 236 6338
9019.0116 QFRVYPELPKPSISS CEA.137 CEA 137 1780 1727 2916 7976
9019.0117 KPSISSNNSKPVEDK CEA.146 CEA 146 405 919 2111 6959 407
9019.0118 YLWWVNNQSLPVSPR CEA.176 CEA 176 2.4 100 832 203 80 17
9019.0119 SDSVILNVLYGPDAP CEA.226 CEA 226 111 255 314 1453 5236
9019.0120 LNVLYGPDAPTISPL CEA.231 CEA 231 331 649 1378 -- 410
9019.0121 APTISPLNTSYRSGE CEA.239 CEA 239 2431 295 49 5994 10,607
9019.0122 QYSWFVNGTFQQSTQ CEA.268 CEA 268 5983 21 7830 364 216
9019.0123 QELFIPNITVNNSGS CEA.282 CEA 282 147 644 25 227 379 1658
9019.0124 RTTVTTITVYAEPPK CEA.310 CEA 310 4115 259 697 32 649
9019.0125 TITVYAEPPKPFITS CEA.315 CEA 315 12,755 539 -- 12,658 5704
8230 9019.0126 YLWWVNNQSLPVSPR CEA.354 CEA 354 1123 234 12 248 88
28 9019.0127 SDPVILNVLYGPDDP CEA.404 CEA 404 384 592 347 3732 2248
9019.0128 SYTYYRPGVNLSLSC CEA.423 CEA 423 1.6 4425 6.8 4036 300 5.4
9019.0129 YSWLIDGNIQQHTQE CEA.447 CEA 447 1407 95 9827 9019.0130
NSGLYTCQANNSASG CEA.471 CEA 471 49 33 37 96 8139 9019.0131
RTTVKTITVSAELPK CEA.488 CEA 488 89 1267 58 54 11 4.2 9019.0132
TITVSAELPKPSISS CEA.493 CEA 493 223 74 9393 6997 3624 29 9019.0133
KPSISSNNSKPVEDK CEA.502 CEA 502 146 403 1404 5564 121 9019.0134
YLWWVNGQSLPVSPR CEA.532 CEA 532 1.4 2.5 1356 188 12 9019.0135
VCGIQNSVSANRSDP CEA.570 CEA 570 44 72 26 1854 1095 9019.0136
QNSVSANRSDPVTLD CEA.574 CEA 574 240 511 1432 -- 274 9019.0137
SSYLSGANLNLSCHS CEA.603 CEA 603 4.0 580 1596 7822 465 9019.0138
QYSWRINGIPQQHTQ CEA.624 CEA 624 472 43 1203 311 11,900 9019.0139
INGIPQQHTQVLFIA CEA.629 CEA 629 682 181 680 942 31 9019.0140
NGTYACFVSNLATGR CEA.650 CEA 650 839 818 11 558 30 20 9019.0141
YACFVSNLATGRNNS CEA.653 CEA 653 183 774 225 41 327 531 9019.0142
NNSIVKSITVSASGT CEA.665 CEA 665 34 103 43 1.8 128 34 9019.0143
SITVSASGTSPGLSA CEA.671 CEA 671 2807 75 11 3374 1559 9019.0144
SPGLSAGATVGIMIG CEA.680 CEA 680 3507 4191 2000 2380 92 1622.05
TVGIMIGVLVGVALI CEA.688 CEA 688 384 -- -- -- 4454 9019.0006
HQLLCCEVETIRRAY Cyclin D1.3 Cyclin D1 3 953 21 746 256 4200 11,553
9019.0146 DANLLNDRVLRAMLK Cyclin D1.19 Cyclin D1 19 1463 2342 --
9019.0147 NDRVLRAMLKAEETC Cyclin D1.24 Cyclin D1 24 1178 1963
12,160 9019.0148 RAMLKAEETCAPSVS Cyclin D1.29 Cyclin D1 29 407 --
360 375 12,517 7793 9019.0149 FKCVQKEVLPSMRKI Cyclin D1.45 Cyclin
D1 45 4099 3615 16,056 9019.0012 QKEVLPSMRKIVATW Cyclin D1.49
Cyclin D1 49 9825 111 12,182 1102 3720 481 9019.0150
LPSMRKIVATWMLEV Cyclin D1.53 Cyclin D1 53 8.5 826 238 28 123 4.6
9019.0151 MRKIVATWMLWVCEE Cyclin D1.56 Cyclin D1 56 764 7953 --
1982 249 9019.0011 MLEVCEEQKCEEEVF Cyclin D1.64 Cyclin D1 64 --
9019.0152 EEEVFPLAMNYLDRF Cyclin D1.74 Cyclin D1 74 850 2247 3070
2228 1597 9019.0153 VFPLAMNYLDRFLSL Cyclin D1.77 Cyclin D1 77 146
107 2332 1567 609 3332 9019.0007 DRFLSLEPVKKSRLQ Cyclin D1.86
Cyclin D1 86 16 290 18 61 159 1057 9019.0154 DRFLSLEPVKKSRLQ Cyclin
D1.86 Cyclin D1 86 15 60 59 251 1831 9019.0155 LEPVKKSRLQLLGAT
Cyclin D1.91 Cyclin D1 91 102 5112 695 13,659 2152 9019.0156
RLQLLGATCMFVASK Cyclin D1.98 Cyclin D1 98 12 -- 91 633 1439 468
9019.0157 TCMFVASKMKETIPL Cyclin D1.105 Cyclin D1 105 262 342 5454
1744 17 9019.0158 ASKMKETIPLTAEKL Cyclin D1.110 Cyclin D1 110 130
-- 1992 -- 220 1622.01 TIPLTAEKLCIYTDN Cyclin D1.116 Cyclin D1 116
253 11,708 1230 -- -- -- 9019.0159 KLCIYTDNSIRPEEL Cyclin D1.123
Cyclin D1 123 1915 64 95 241 3172 1105 9019.0009 DNSIRPEELLQMELL
Cyclin D1.129 Cyclin D1 129 4554 147 4677 2803 16,500 6648
9019.0160 DNSIRPEELLQMELL Cyclin D1.129 Cyclin D1 129 1533 1345
3440 9019.0161 PEELLQMELLLVNKL Cyclin D1.134 Cyclin D1 134 1274
1027 313 603 401 9019.0010 EELLQMELLLVNKLK Cyclin D1.135 Cyclin D1
135 3385 1622.06 LLQMELLLVNKLKWN Cyclin D1.139 Cyclin D1 139 39 --
3539 6.1 387 2196 9019.0163 MELLLVNKLKWNLAA Cyclin D1.140 Cyclin D1
140 46 9006 177 491 2411 1797 9019.0164 VNKLKWNLAAMTPHD Cyclin
D1.145 Cyclin D1 145 46 1419 88 781 747 382 9019.0165
KWNLAAMTPHDFIEH Cyclin D1.149 Cyclin D1 149 33 6249 3405 653 122
1101 9019.0013 WNLAAMTPHDFIEHF Cyclin D1.150 Cyclin D1 150 6425
9019.0166 PHDFIEHFLSKMPEA Cyclin D1.157 Cyclin D1 157 1246 1299
1160 9019.0167 NKQIIRKHAQTFVAL Cyclin D1.174 Cyclin D1 174 4.7 561
6.5 23 25 4.4 9019.0168 AQTFVALCATDVKFI Cyclin D1.182 Cyclin D1 182
8.4 551 26 133 55 13 9019.0169 VKFISNPPSMVAAGS Cyclin D1.193 Cyclin
D1 193 6.7 4128 12 18 117 304 9019.0170 PPSMVAAGSVVAAVQ Cyclin
D1.199 Cyclin D1 199 6.8 -- 12 26 1718 133 9019.0171
VAAVQGLNLRSPNNF Cyclin D1.209 Cyclin D1 209 44 18,558 226 532 4248
161 9019.0172 IEALLESSLRQAQQN Cyclin D1.251 Cyclin D1 251 2608 18
-- 9019.0014 EALLESSLRQAQQNM Cyclin D1.252 Cyclin D1 252 8212 151
605 1019 12,908 -- 9019.0024 LAALCRWGLLLALLP Her2/neu.3 Her2/neu 3
2044 5394 7995 9019.0025 WGLLLALLPPGAAST Her2/neu.9 Her2/neu 9 1687
750 0.93 219 16,366 1622.02 LLALLPPGAASTQVC Her2/neu.12 Her2/neu 12
17 5146 118 -- 7181 9019.0027 GTDMKLBLPASPETH Her2/neu.28 Her2/neu
28 2117 1693 6814 9019.0028 RHLYQGCQVVQGNLE Her2/neu.47 Her2/neu 47
1435 422 4948 9019.0029 GCQVVQGNLELTYLP Her2/neu.52 Her2/neu 52
2600 2739 1972 9019.0030 NLELTYLPTNASLSF Her2/neu.59 Her2/neu 59
4.9 7356 6.2 2.7 38 7.2 9019.0031 LTYLPTNASLSFLQD Her2/neu.62
Her2/neu 62 9.7 3364 19 16 80 15 9019.0032 IQEVQGYVLIAHNQV
Her2/neu.77 Her2/neu 77 57 7763 111 178 102 35 9019.0033
VVLLAHNQVRQVPLQ Her2/neu.83 Her2/neu 83 28 454 93 104 1185 92
9019.0034 HNQVRQVFLQRLRIV Her2/neu.88 Her2/neu 88 950 971 840 78
1303 80 9019.0035 VRQVPLQRLRIVRGT Her2/neu.91 Her2/neu 91 3065 1796
218 9019.0001 GTQLFEDNYALAVLD Her2/neu.104 Her2/neu 104 210 29 640
3923 14,921 129 9019.0036 GDPLNNTTFVTGASP Her2/neu.120 Her2/neu 120
6356 7468 13,172 9019.0037 TTPVTGASPGGLREL Her2/neu.126 Her2/neu
126 992 2417 675 13,198 1843 9019.0038 Her2/neu.141 Her2/neu 141
712 110 1541 9019.0039 Her2/neu.146 Her2/neu 146 71 40 12 769 2486
9019.0040 GGVIIQRNPQLCYQD Her2/neu.151 Her2/neu 151 142 158 93 1845
14,279 9019.0041 NPQLCYQDTILWNDI Her2/neu.158 Her2/neu 158 3653 369
-- 9019.0042 Her2/neu.265 Her2/neu 265 101 136 1627 1324 9019.0043
STDVGSCTLVCPLHN Her2/neu.305 Her2/neu 305 2872 265 -- 2139
9019.0044 CYGLGMEHLREVRAV Her2/neu.342 Her2/neu 342 139 2970 1027
493 5122 271 9019.0045 MEHLREVRAVISANI Her2/neu.347 Her2/neu 347
9.6 3913 513 12 200 9.7 9019.0046 LREVRAVTSANIQEF Her2/neu.350
Her2/neu 350 17 43 8.2 50 12 9019.0047 Her2/neu.367 Her2/neu 367
139 989 121 171 513 45 9019.0048 Her2/neu.378 Her2/neu 378 10,101
3974 1724 2828 9019.0049 Her2/neu.389 Her2/neu 389 1112 9019.0050
ITGYLYISAWPDSIP Her2/neu.406 Her2/neu 406 96 243 1771 8.5 136
9019.0051 Her2/neu.416 Her2/neu 416 -- -- -- 9019.0052 Her2/neu.422
Her2/neu 422 1.3 345 63 33 26 7.1 9019.0053 NLQVIRGRILHNGAY
Her2/neu.427 Her2/neu 427 1.9 6879 206 3394 12 9019.0054
RGRILHNGAYSLTLQ Her2/neu.432 Her2/neu 432 2.4 710 450 129 2845 5.6
9019.0055 SLTLQGLGISWLGLR Her2/neu.442 Her2/neu 442 93 143 110 409
3096 9019.0056 GLGISWLGLRSLREL Her2/neu.447 Her2/neu 447 50 122 41
163 3.1 55 9019.0057 Her2/neu.455 Her2/neu 455 7.1 -- 646 14 142
9019.0058 GLALIHHNTHLCFVH Her2/neu.464 Her2/neu 464 465 414 171 477
277 9019.0059 NTHLCFVHTVPWDQL Her2/neu.471 Her2/neu 471 416 796 207
116 178 9019.0060 DECVGEGLACHQICA Her2/neu.502 Her2/neu 502 459
1968 3405 2337 2097 9019.0061 Her2/neu.518 Her2/neu 518 1915 6742
9019.0062 Her2/neu.532 Her2/neu 532 462 1020 4595 -- 540 9019.0063
Her2/neu.543 Her2/neu 543 262 788 9351 812 4861 9019.0064
LQGLPREYVNARECL Her2/neu.547 Her2/neu 547 354 1995 211 1144 653
1903 9019.0065 PSGVKPDLSYMPIWK Her2/neu.601 Her2/neu 601 1832 1578
1525 2688 9019.0066 ASPLTSIISAVVGIL Her2/neu.648 Her2/neu 648 15
10,905 29 36 712 24 9019.0067 ISAVVGILLVVVLGV Her2/neu.655 Her2/neu
655 5153 450 2996 447 941 9019.0068 ILLVVVLGVVFGILI Her2/neu.661
Her2/neu 661 -- 665 3532 376 780 9019.0069 VLGVVFGILIKRRQQ
Her2/neu.666 Her2/neu 666 67 2449 177 335 101 17 9019.0070
QQKIRKYTMRRLLQE Her2/neu.679 Her2/neu 679 303 3782 5396 -- 44
9019.0071 IRKYTMRRLLQETEL Her2/neu.682 Her2/neu 682 665 2766 2305
1050 722 9019.0072 Her2/neu.712 Her2/neu 712 266 3030 176 9019.0073
ETELRKVKVLGSGAF Her2/neu.717 Her2/neu 717 284 19,518 246 27 845 101
9019.0074 KVKVLGSGAFGTYYK Her2/neu.722 Her2/neu 722 64 8.0 204
10,992 77 9019.0075 GENYKIPVAIKYLEE Her2/neu.743 Her2/neu 743 491
1055 488 2093 1622.00 Her2/neu.747 Her2/neu 747 1295 125 1178 --
9019.0077 AYVMAGVGSPYVSRL Her2/neu.771 Her2/neu 771 92 164 171 596
45 9019.0078 MAGVGSPYVSRLIGI Her2/neu.774 Her2/neu 774 2050 1651
352 9019.0079 SRLLGSCLTSTVQLV Her2/neu.783 Her2/neu 783 80 2923 85
13 90 9.0 9019.0080 TVQLVTQLMPYGCLL Her2/neu.793 Her2/neu 793 164
215 433 4326 1288 9019.0081 RGRLGGQBLLNWCMQ Her2/neu.814 Her2/neu
814 1059 1412 2029 9019.0082 Her2/neu.822 Her2/neu 822 944 558 195
1094 380 9019.0083 CMQLAKGMSYLEDVR Her2/neu.826 Her2/neu 826 959
2651 867 1040 116 9019.0084 Her2/neu.832 Her2/neu 832 123 27 957
1357 4315 5496 9019.0085 VRLVHRDLAARNVLV Her2/neu.839 Her2/neu 839
59 1503 105 268 561 356 9019.0086 HRDLAARVVLVRSPS Her2/neu.843
Her2/neu 843 153 401 765 11,210 1332 9019.0087 Her2/neu.848
Her2/neu 848 65 1275 209 197 10,536 118 9019.0088 Her2/neu.865
Her2/neu 865 12 30 14 250 161 664 9019.0008 IKWMALERILRRRFT
Her2/neu.886 Her2/neu 886 16 10 37 1075 435 1795 9019.0089
Her2/neu.903 Her2/neu 903 163 2175 9019.0090 IDVWSYGVTVWELMT
Her2/neu.903 Her2/neu 903 163 2760 3621 1900 546 9019.0091
GVTVWELMTFGAKFV Her2/neu.909 Her2/neu 909 40 377 4.1 2107 558
9019.0092 VWELMTTGAKPYDCI Her2/neu.912 Her2/neu 912 36 676 144 4704
191 9019.0093 AKPYDGIFAREIPDL Her2/neu.920 Her2/neu 920 116 -- --
12,548 41 1622.04 ICTIDVYMIMVKCWM Her2/neu.946 Her2/neu 946 -- 717
-- 955 -- 9019.0094 Her2/neu.950 Her2/neu 950 1312 7007 274 297
9019.0095 RPBFRELVSEPSBMA Her2/neu.966 Her2/neu 966 26 6218 38 62
151 309 9019.0096 FRELVSEPSBMARDP Her2/neu.969 Her2/neu 969 20 150
22 51 1487 5085 9019.0004 Her2/neu.970 Her2/neu 970 29 35 512 2224
655 1423 9019.0097 DGDLGMGAAKGLQSL Her2/neu.1087 Her2/neu 1087 110
254 506 5799 828 9019.0099 AKGLQSLPTHDPSFL Her2/neu.1095 Her2/neu
1095 149 194 19 3864 4459 9019.0000 Her2/neu.1109 Her2/neu 1109
1367 18 25 11,089 197 9019.0100 PEYVNQPDVRPQPPS Her2/neu.1137
Her2/neu 1137 5165 150 -- 9019.0101 BGPLPAAKPAGATLE Her2/neu.1154
Her2/neu 1154 17,238 -- 7463 9019.0102 Her2/neu.1164 Her2/neu 1164
1812 2792 9019.0103 KDVFAFGGAVENPEY Her2/neu.1182 Her2/neu 1182
1505 -- 1577 9019.0173 LPRVGCPALPLPPPP IGFBP2.2 IGFBP2 2 1906 6543
-- 9019.0174 ALPLPPPPLLPLLPL IGFBP2.9 IGFBP2 9 174 18 1.2 20 226
9019.0175 PPPLLPLLPLLLLLL IGFBP2.14 IGFBP2 14 15 5816 15 16 65 13
9019.0176 LLPLLPLLLLLLGAS IGFBP2.17 IGFBP2 17 119 -- 337 35 674 964
9019.0177 PLLLLLLGASGGGGG IGFBP2.22 IGFBP2 22 26 19,033 339 2144
1122 5982 9019.0178 AEVLFRCEPCTPERL IGFBP2.39 IGFBP2 39 1285 1611
15,970 9019.0179 PERLAACGPPPVAPP IGFBP2.50 IGFBP2 50 28 5545 163
4353 -- 9019.0180 PPPVAPPAAVAAVAG IGFBP2.58 IGFBP2 58 178 -- 380 91
-- 2684 9019.0181 GARMPCAELVREPGC IGFBP2.73 IGFBP2 73 164 11,639
13,072 -- -- 9019.0015 CAELVREPGCGCCSV IGFBP2.78 IGFBP2 78 12,298
9019.0016 IGFBP2.93 IGFBP2 93 -- 9019.0182 ELPLQALVMGEGTCE
IGFBP2.121 IGFBP2 121 1502 6782 15,638 9019.0017 QALVMGBGTCEKRRD
IGFBP2.125 IGFBP2 125 2240 9019.0183 IGFBP2.157 IGFBP2 157 1153
1196 4623 9019.0184 IGFBP2.169 IGFBP2 169 1021 791 6177 9019.0185
LKSGMKELAVFREKV IGFBP2.184 IGFBP2 184 607 -- 861 862 34 --
9019.0186 KELAVFREKVTEQHR IGFBP2.190 IGFBP2 190 2045 28 9019.0018
ELAVFREKVTEQHRQ IGFBP2.190 IGFBP2 190 5021 9019.0019
REKVTEQHRQMGKGG IGFBP2.195 IGFBP2 195 2839 9019.0187
GKHHLGLEEPKKLRP IGFBP2.209 IGFBP2 209 238 1654 2756 6484 3097
9019.0020 KHHLGLEEPKKLRPP IGFBP2.210 IGFBP2 210 4016 9019.0188
IGFBP2.217 IGFBP2 217 1258 806 1122 9019.0189 LDQVLERISTMRLPD
IGFBP2.234 IGFBP2 234 795 452 25 20 18 5.2 9019.0021
TMRLPDERGPLEHLY IGFBP2.243 IGFBP2 243 -- 9019.0190 ERGPLEHLYSLHIPS
IGFBP2.249 IGFBP2 249 7.7 -- 497 29 110 18 9019.0191
GLYNLKQCKMSLNGQ IGFBP2.268 IGFBP2 268 923 -- 743 2835 5589 1791
9019.0192 TGKLIQGAPTIRGDP IGFBP2.293 IGFBP2 293 148 9554 40 27 405
883 9019.0022 IGFBP2.300 IGFBP2 300 4031 31 1643 2908 -- 16,779
9019.0023 CHLFYNEQQEARGVH IGFBP2.309 IGFBP2 309 162 1600 3187 -- --
IC.sub.50 nM purified HLA DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4
DRB5 Peptide Sequence *0802 *0901 *1101 *1201 *1302 *1501 *0101
*0101 *0101 9019.0104 RWCIPWQRLLLTASL 263 4132 191 1558 2326 61 --
339 4014 9019.0105 LLTFWNPPTTAKLTI 174 5779 52 4995 245 46 -- 2171
31 9019.0106 TAKLTIESTPFNVAE 1736 4019 5977 2907 35 140 -- 53 3350
9019.0107 EVLLLVHNLPQHLFG 59 989 40 5.4 0.36 4.7 334 50 1088
9019.0108 YSWYKGERVDGNRQI 8432 -- 1840 -- 533 306 3002 453 1043
9019.0109 NRQIIGYVIGTQQAT 46 345 36 4351 990 2.6 -- 5.2 2230
9019.0110 QYVIGTQQATPGPAY 5877 43 836 6.3 10,223 9019.0111
GPAYSGREIIYPNAS 154 9019.0112 GREIIYPNASLLIQN 1959 1355 2209 212 24
49 4035 43 10,612 9019.0113 DIGFYTLHVIKSDLV 90 83 174 174 1072 65
14,943 18 564 9019.0114 FLTLHVIKSDLVNEE 514 718 6385 616 1340 14
14,343 22 4501 9019.0005 LHVIKSDLVNEEATG -- -- 18,399 -- 394 376 --
111 -- 9019.0115 KSDLVNEEATGQFRV 9963 9019.0116 QFRVYPELPKPSISS 786
9019.0117 KPSISSNNSKPVEDK -- 23 97 5977 -- 9019.0118
YLWWVNNQSLPVSPR 119 1912 22 1511 22 116 248 555 928 9019.0119
SDSVILNVLYGPDAP 9210 83 351 612 -- 9019.0120 LNVLYGPDAPTISPL -- 218
583 10,798 -- 9019.0121 APTISPLNTSYRSGE 3943 125 1706 1047 51
9019.0122 QYSWFVNGTFQQSTQ 230 14,768 -- 11,448 2661 9019.0123
QELFIPNITVNNSGS 293 1086 358 1299 26 740 -- 3880 3869 9019.0124
RTTVTTITVYAEPPK -- 2977 83 6287 14,732 9019.0125 TITVYAEPPKPFITS --
2322 62 -- 9255 9019.0126 YLWWVNNQSLPVSPR 243 299 33 1121 1921 227
1088 861 2284 9019.0127 SDPVILNVLYGPDDP 5432 161 5699 9262 --
9019.0128 SYTYYRPGVNLSLSC 21 1372 776 371 7.2 46 2626 1784 135
9019.0129 YSWLIDGNIQQHTQE 1312 9019.0130 NSGLYTCQANNSASG 7338 1024
14,891 100 4717 9019.0131 RTTVKTITVSAELPK 3763 367 6988 2758 962 29
-- 1263 1917
9019.0132 TITVSAELPKPSISS -- 6871 -- -- 1076 1672 -- 10,349 3856
9019.0133 KPSISSNNSKPVEDK -- 4.1 138 -- -- 9019.0134
YLWWVNGQSLPVSPR 3195 314 182 4295 1348 9019.0135 VCGIQNSVSANRSDP --
921 8979 1051 36 9019.0136 QNSVSANRSDPVTLD -- 2.7 6657 2105 5816
9019.0137 SSYLSGANLNLSCHS -- 37 13,028 42 14,095 9019.0138
QYSWRINGIPQQHTQ 151 70 2074 2286 1121 9019.0139 INGIPQQHTQVLFIA --
256 8287 2700 -- 9019.0140 NGTYACFVSNLATGR 70 377 2174 2052 30 2351
6963 3247 37 9019.0141 YACFVSNLATGRNNS 1774 4520 217 2399 107 1237
-- 1569 17 9019.0142 NNSIVKSITVSASGT 184 469 209 1328 4.4 274
15,808 26 2280 9019.0143 SITVSASGTSPGLSA 3319 592 3110 174 15,069
9019.0144 SPGLSAGATVGIMIG -- 80 3929 2591 -- 1622.05
TVGIMIGVLVGVALI -- 5637 7770 12,094 384 9019.0006 HQLLCCEVETIRRAY
16,297 5607 3471 5585 349 325 -- 60 2016 9019.0146 DANLLNDRVLRAMLK
286 9019.0147 NDRVLRAMLKAEETC 319 9019.0148 RAMLKAEETCAPSVS -- 5017
9145 -- 16,129 15,733 -- 313 1341 9019.0149 FKCVQKEVLPSMRKI 1587
9019.0012 QKEVLPSMRKIVATW 1155 1088 58 1121 700 338 -- 108 2019
9019.0150 LPSMRKIVATWMLEV 1182 137 836 145 8.5 7.1 8449 50 47
9019.0151 MRKIVATWMLWVCEE -- 356 87 281 17,021 9019.0011
MLEVCEEQKCEEEVF 9019.0152 EEEVFPLAMNYLDRF 3414 26 77 72 4444
9019.0153 VFPLAMNYLDRFLSL 259 19,713 27 79 5.4 39 239 2.6 2005
9019.0007 DRFLSLEPVKKSRLQ 37 18,378 46 4128 -- 394 -- 399 3.0
9019.0154 DRFLSLEPVKKSRLQ 51 285 1075 227 2.6 9019.0155
LEPVKKSRLQLLGAT 1248 221 208 102 731 9019.0156 RLQLLGATCMFVASK 3144
-- 831 513 227 277 -- 421 504 9019.0157 TCMFVASKMKETIPL 61 1031
1113 2423 36 9019.0158 ASKMKETIPLTAEKL 321 550 1294 2461 2364
1622.01 TIPLTAEKLCIYTDN -- -- -- -- -- 5360 -- 738 253 9019.0159
KLCIYTDNSIRPEEL 16,263 15,928 -- -- 879 25 -- 33 4620 9019.0009
DNSIRPEELLQMELL -- 3494 4757 87 18,256 9019.0160 DNSIRPEELLQMELL
959 9019.0161 PEELLQMELLLVNKL 1091 44 1119 11 2802 9019.0010
EELLQMELLLVNKLK 1622.06 LLQMELLLVNKLKWN 765 6007 187 1325 44 28 --
321 39 9019.0163 MELLLVNKLKWNLAA 368 3090 48 162 4.9 246 -- 39 19
9019.0164 VNKLKWNLAAMTPHD 702 449 1043 116 3.0 356 5867 1839 2519
9019.0165 KWNLAAMTPHDFIEH 18,625 4876 11,907 194 332 356 -- 576 41
9019.0013 WNLAAMTPHDFIEHF 9019.0166 PHDFIEHFLSKMPEA 820 9019.0167
NKQIIRKHAQTFVAL 195 236 34 3.9 2.0 3.3 342 8.7 23 9019.0168
AQTFVALCATDVKFI 445 936 276 132 219 97 -- 46 18 9019.0169
VKFISNPPSMVAAGS 319 752 88 21 24 84 5290 290 826 9019.0170
PPSMVAAGSVVAAVQ 1401 301 166 10,090 55 26 -- 91 957 9019.0171
VAAVQGLNLRSPNNF 10,850 -- 11,089 2018 171 1205 -- 296 3541
9019.0172 IEALLESSLRQAQQN 12,776 9019.0014 EALLESSLRQAQQNM 756 4755
8176 4028 -- 9019.0024 LAALCRWGLLLALLP 704 9019.0025
WGLLLALLPPGAAST 12 521 21 33 337 1622.02 LLALLPPGAASTQVC 944 10,697
17,445 19,806 17 9019.0027 GTDMKLBLPASPETH 14,523 9019.0028
RHLYQGCQVVQGNLE 5043 9019.0029 GCQVVQGNLELTYLP 417 9019.0030
NLELTYLPTNASLSF 94 3055 30 141 105 23 -- 29 189 9019.0031
LTYLPTNASLSFLQD 426 4081 213 150 47 132 141 1633 173 9019.0032
IQEVQGYVLIAHNQV 213 302 165 3438 103 75 13,508 546 1361 9019.0033
VVLLAHNQVRQVPLQ 300 358 208 302 1.9 679 649 124 18 9019.0034
HNQVRQVFLQRLRIV 85 6044 21 42 270 340 -- 18 173 9019.0035
VRQVPLQRLRIVRGT 2545 9019.0001 GTQLFEDNYALAVLD 9135 4.0 450 3744
9019.0036 GDPLNNTTFVTGASP 1030 9019.0037 TTPVTGASPGGLREL 11,154 605
17,148 2319 3001 9019.0038 2237 786 4405 2245 16,271 9019.0039 642
343 1183 511 1878 9019.0040 GGVIIQRNPQLCYQD 1720 34 106 351 13,512
9019.0041 NPQLCYQDTILWNDI 5074 9019.0042 521 2216 740 441 2009
9019.0043 STDVGSCTLVCPLHN 6781 9019.0044 CYGLGMEHLREVRAV -- -- 3064
18,979 25 690 -- 444 3716 9019.0045 MEHLREVRAVISANI 95 1345 242 221
23 86 -- 81 2.6 9019.0046 LREVRAVTSANIQEF 456 5187 641 161 1.5 27
-- 163 94 9019.0047 3060 206 635 316 4567 9019.0048 12,191 2905 805
654 -- 9019.0049 2322 9019.0050 ITGYLYISAWPDSIP 2573 751 152 270 67
9019.0051 -- 9019.0052 148 859 96 486 80 33 -- 67 17 9019.0053
NLQVIRGRILHNGAY 119 4217 173 47 9.9 3.3 4320 446 28 9019.0054
RGRILHNGAYSLTLQ 5077 430 773 40 1.3 5.4 358 562 82 9019.0055
SLTLQGLGISWLGLR 6307 1597 50 22 -- 9019.0056 GLGISWLGLRSLREL 1538
1140 2258 436 3030 5.2 -- 154 2048 9019.0057 1075 360 409 16 24
16,162 726 9019.0058 GLALIHHNTHLCFVH 2802 18 164 357 6081 9019.0059
NTHLCFVHTVPWDQL 793 175 1431 117 7390 9019.0060 DECVGEGLACHQICA
4976 323 6267 1117 12,277 9019.0061 2912 9019.0062 16,162 146 285
1923 7043 9019.0063 254 549 685 2572 9019.0064 LQGLPREYVNARECL 405
670 423 2551 49 9019.0065 PSGVKPDLSYMPIWK 1531 9019.0066
ASPLTSIISAVVGIL 3089 118 511 1431 14 59 18,926 1500 216 9019.0067
ISAVVGILLVVVLGV 5138 443 6005 3109 -- 9019.0068 ILLVVVLGVVFGILI
2454 478 7117 11,015 -- 9019.0069 VLGVVFGILIKRRQQ 35 -- 12 268 17
185 -- 958 36 9019.0070 QQKIRKYTMRRLLQE 44 2.0 93 340 9019.0071
IRKYTMRRLLQETEL 45 2583 1.6 303 2207 9019.0072 2132 1318 129 368
1223 9019.0073 ETELRKVKVLGSGAF 189 5423 176 2472 205 -- 452 1020
9019.0074 KVKVLGSGAFGTYYK 1711 1303 244 1380 1392 9019.0075
GENYKIPVAIKYLEE 4555 1149 729 84 8353 1622.00 4158 701 611 1305
9019.0077 AYVMAGVGSPYVSRL 1798 402 24 5060 9019.0078
MAGVGSPYVSRLIGI 1508 9019.0079 SRLLGSCLTSTVQLV 634 137 80 446 4.7
39 3567 481 392 9019.0080 TVQLVTQLMPYGCLL 11,126 3394 9.4 16 3001
9019.0081 RGRLGGQBLLNWCMQ 2367 9019.0082 159 2082 799 3359 92
9019.0083 CMQLAKGMSYLEDVR 405 2232 1002 3005 130 9019.0084 244 3769
567 2543 467 9019.0085 VRLVHRDLAARNVLV 16 57 1097 298 3425
9019.0086 HRDLAARVVLVRSPS 1648 316 221 525 302 9019.0087 717 5778
513 15 29 16,142 742 4.9 9019.0088 312 9620 133 65 140 3.3 -- 62
3.4 9019.0008 IKWMALERILRRRFT 515 9282 136 241 1118 11 -- 340 3.3
9019.0089 1150 16,270 2726 618 5301 9019.0090 IDVWSYGVTVWELMT 2639
467 1879 -- 5425 9019.0091 GVTVWELMTFGAKFV 315 8368 20 1171 34
9019.0092 VWELMTTGAKPYDCI 1952 1553 245 3565 65 9019.0093
AKPYDGIFAREIPDL -- 19,575 6957 -- 3041 1622.04 ICTIDVYMIMVKCWM 1480
-- 2652 -- -- 9019.0094 172 395 1303 607 716 9019.0095
RPBFRELVSEPSBMA 376 2321 125 1779 12,182 348 -- 351 26
9019.0096 FRELVSEPSBMARDP 1714 -- 331 -- -- 124 4537 1282 380
9019.0004 790 1401 40 240 1405 901 227 45 9019.0097 DGDLGMGAAKGLQSL
2233 3234 1634 896 2141 9019.0099 AKGLQSLPTHDPSFL 6806 3991 1665
572 -- 9019.0000 94 380 531 9019.0100 PEYVNQPDVRPQPPS 1714
9019.0101 BGPLPAAKPAGATLE 10,247 9019.0102 9019.0103
KDVFAFGGAVENPEY 16,146 9019.0173 LPRVGCPALPLPPPP 8936 9019.0174
ALPLPPPPLLPLLPL 1087 41 1521 263 10 9019.0175 PPPLLPLLPLLLLLL 86
307 121 23 1322 5.0 16,239 2.1 121 9019.0176 LLPLLPLLLLLLGAS 213
5893 458 320 2022 182 -- 19 2390 9019.0177 PLLLLLLGASGGGGG --
12,919 19,255 2161 252 -- 216 -- 9019.0178 AEVLFRCEPCTPERL 5774
9019.0179 PERLAACGPPPVAPP 3541 3618 4054 4455 19,615 9019.0180
PPPVAPPAAVAAVAG -- 317 -- -- 237 1378 -- -- 9019.0181
GARMPCAELVREPGC 2968 16,279 -- 4697 -- 9019.0015 CAELVREPGCGCCSV
9019.0016 9019.0182 ELPLQALVMGEGTCE 9167 9019.0017 QALVMGBGTCEKRRD
9019.0183 2518 9019.0184 5686 9019.0185 LKSGMKELAVFREKV 260 -- 163
1768 4974 91 -- 417 843 9019.0186 KELAVFREKVTEQHR 9019.0018
ELAVFREKVTEQHRQ 9019.0019 REKVTEQHRQMGKGG 9019.0187 GKHHLGLEEPKKLRP
16,789 3029 1378 6390 9019.0020 KHHLGLEEPKKLRPP 9019.0188 1213
9019.0189 LDQVLERISTMRLPD 1607 52 467 314 1052 84 -- 367 223
9019.0021 TMRLPDERGPLEHLY 9019.0190 ERGPLEHLYSLHIPS 9361 1995 50
1149 23 -- 1648 4000 9019.0191 GLYNLKQCKMSLNGQ 204 9434 2660 413
561 223 -- 1613 5609 9019.0192 TGKLIQGAPTIRGDP 5169 709 7989 2091
927 1783 2191 405 36 9019.0022 -- -- -- 16,917 1674 3669 191 2510
-- 9019.0023 CHLFYNEQQEARGVH -- -- -- 1855 145 -- 18,902 5310 -- --
indicates binding affinity .gtoreq. 20.000 nM. indicates data
missing or illegible when filed
TABLE-US-00003 TABLE II Breast/Ovarian HLA-DR Supertype Candidates
IC.sub.50 nM to purified HLA Peptide DRB1 DRB1 DRB1 DRB1 DRB1 DRB1
DRB1 No. Sequence Source Protein Position 9019.0105 LLTFWNPPTTAKLTI
CEA.24 CEA 24 6.9 16,313 273 52 258 3.7 174 9019.0106
TAKLTIESTPFNVAE CEA.33 CEA 33 72 613 106 41 383 70 1736 9019.0107
EVLILVHNLPQHLFQ CEA.50 CEA 50 2.7 830 3.4 1.7 30 5.4 19 9019.0108
YSWYKGERVDGNRQI CEA.65 CEA 65 511 -- 34 585 360 866 842 9019.0109
CEA.76 CEA 76 216 -- 108 1.5 129 46 16 9019.0112 GREIIYPNASLLIQN
CEA.97 CEA 97 62 433 251 88 550 29 9019.0113 DTQFYTLHVEKSDLV
CEA.116 CEA 116 64 964 84 260 95 23 70 9019.0114 CEA.119 CEA 119
101 80 160 41 46 9019.0118 CEA.176 CEA 176 2.4 100 872 203 80 17
119 9019.0123 QELFIPNITVNNSGS CEA.282 CEA 282 147 644 25 227 379
1658 293 9019.0126 YLWWVNNQSLPVSPR CEA.354 CEA 354 1128 214 12 248
83 28 243 9019.0128 SYTYYRPGVNLSLSC CEA.423 CEA 423 1.6 4425 6.8
4036 300 5.4 21 9019.0131 CEA.488 CEA 488 80 84 11 1.5 9019.0140
NGTYACFVSNLATQR CEA.650 CEA 650 539 818 11 558 30 20 9019.0141
YACFVSNLATGRNNS CEA.653 CEA 653 183 774 225 41 327 531 1174
9019.0142 CEA.665 CEA 665 34 103 43 1.8 128 34 134 9019.0006
HQLLCCEVETTRRAY Cyclin D1.3 Cyclin D1 3 953 21 740 256 4209 11,553
16,297 9019.0012 Cyclin D1.49 Cyclin D1 49 111 12,162 1102 3720 451
1155 9019.0150 LPSNRKIVATWMLEV Cyclin D1.53 Cyclin D1 53 8.5 820
238 28 123 4.6 1182 9019.0153 VFPLAMNYLDRFLSL Cyclin D1.77 Cyclin
D1 77 146 107 2332 1567 609 3332 259 9019.0007 DRFLSLEPVKKSRLQ
Cyclin D1.86 Cyclin D1 86 16 290 18 61 159 1057 37 9019.0156
RLQLLGATCMFVASK Cyclin D1.98 Cyclin D1 98 12 -- 91 533 1439 458
3164 1622.06 LLQMELLLVNKLKWN Cyclin D1.137 Cyclin D1 137 39 -- 3539
6.4 332 2196 735 9019.0163 MELLLVNKLKWNLAA Cyclin D1.140 Cyclin D1
140 46 9006 177 191 2411 1797 358 9019.0164 VNKLKWNLAAMTPHD Cyclin
D1.145 Cyclin D1 145 46 1419 88 781 747 382 712 9019.0165 Cyclin
D1.149 Cyclin D1 149 33 6249 3405 553 122 1101 18,625 9019.0167
NKQTRKIIAQTFVAL Cyclin D1.174 Cyclin D1 174 4.7 561 6.5 23 25 4.4
135 9019.0168 AQIIVALCATDVRFI Cyclin D1.182 Cyclin D1 182 5.4 551
26 133 55 13 445 9019.0169 Cyclin D1.193 Cyclin D1 193 6.7 4128 12
18 117 304 318 9019.0170 PPSMVAAGSVVAAVQ Cyclin D1.199 Cyclin D1
199 6.8 -- 12 26 3718 133 1401 9019.0171 VAAVQGLNLRSPNNF Cyclin
D1.209 Cyclin D1 209 44 18,558 226 532 4248 161 10,850 9019.0030
NLELTYLPTNASLSF Her2/neu.59 Her2/neu 59 4.9 7356 6.2 2.7 38 7.2 94
9019.0031 LTYLPTNASLSELQD Her2/neu.62 Her2/neu 62 9.7 19 16 60 15
426 9019.0032 Her2/neu.77 Her2/neu 77 57 7763 111 178 102 35 213
9019.0033 YVLIAHNQVRQVPLQ Her2/neu.83 Her2/neu 83 28 454 53 104
1185 92 330 9019.0034 HNQVRQVPLQRLRIV Her2/neu.88 Her2/neu 88 971
840 78 1303 80 15 9019.0035 Her2/neu.347 Her2/neu 347 9.4 2040 12
9.7 9019.0046 LREVRAVTSANIQEF Her2/neu.350 Her2/neu 350 17 3913 43
8.2 50 12 456 9019.0052 LSVFQNLQVIRGRIL Her2/neu.422 Her2/neu 422
1.3 345 6.3 33 26 7.1 148 9019.0054 Her2/neu.432 Her2/neu 432 2.4
713 480 129 2845 5.6 5477 9019.0057 LRSLRELGSGLALIH Her2/neu.455
Her2/neu 455 7.1 -- 896 14 603 142 1475 9019.0009 Her2/neu.666
Her2/neu 666 87 2449 177 555 101 17 15 9019.0079 SRLLGPCLTSTVQLV
Her2/neu.783 Her2/neu 783 80 2923 85 13 90 9.0 654 9019.0087
PIKWMALESILRRRF Her2/neu.885 Her2/neu 885 12 30 14 250 161 664 112
9019.0003 IKWMALESILRRRFT Her2/neu.886 Her2/neu 886 16 10 37 1075
435 1795 515 9019.0004 FSRMARDPQRFVVIQ Her2/neu.976 Her2/neu 976 29
35 512 2224 855 1423 798 9019.0174 ALPLPPPPLLPLLPL IGFBP2.9 IGFBP2
9 174 -- 18 4.2 20 336 1087 9019.0175 PPPLLPLLPLLLLLL IGFBP2.14
IGFBP2 14 15 5816 15 16 65 13 86 9019.0176 LLPLLPLLLLLLGAS
IGFBP2.17 IGFBP2 17 1.9 -- 337 35 674 964 213 9019.0177
PLLLLLLGASGGGGG IGFBP2.22 IGFBP2 22 20 330 2144 1422 9019.0180
IGFBP2.58 IGFBP2 58 178 -- 380 81 -- 2684 -- 9019.0185 IGFBP2.184
IGFBP2 184 687 -- 881 862 34 -- 260 9019.0189 LDQVLERISTMRLPD
IGFBP2.234 IGFBP2 234 735 452 25 29 18 5.2 1997 9019.0190
EROPLEHLYSLHIPN IGFBP2.249 IGFBP2 249 7.5 -- 497 29 110 18 9361
9019.0191 GLYNLKQCKMSLNGQ IGFBP2.268 IGFBP2 268 923 -- 743 2835
5583 1791 204 9019.0192 TGKLIQGAPTIRGDP IGFBP2.293 IGFBP2 293 165
9554 40 27 608 883 5160 IC.sub.50 nM to purified HLA Peptide DRB1
DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 Total No. Sequence XRN 9019.0105
LLTFWNPPTTAKLTI 5779 52 4995 245 46 -- 2171 31 10 9019.0106
TAKLTIESTPFNVAE 4019 5977 2947 35 140 -- 53 3350 9 9019.0107
EVLILVHNLPQHLFQ 989 40 5.4 0.36 4.7 334 30 1165 14 9019.0108
YSWYKGERVDGNRQI -- 1540 -- 533 306 3002 453 1043 8 9019.0109 345 36
4351 990 2.6 -- 5.2 2292 11 9019.0112 GREIIYPNASLLIQN 1399 2209 212
24 49 4035 43 10,612 10 9019.0113 DTQFYTLHVEKSDLV 83 174 174 1072
65 14,943 18 564 13 9019.0114 718 6385 616 1340 14 4501 11
9019.0118 1912 22 1511 22 116 248 555 328 13 9019.0123
QELFIPNITVNNSGS 1086 358 1249 26 740 -- 3889 3869 9 9019.0126
YLWWVNNQSLPVSPR 299 33 1121 1921 227 1081 861 2284 10 9019.0128
SYTYYRPGVNLSLSC 1372 776 378 7.2 46 2621 1784 135 10 9019.0131 1917
7 9019.0140 NGTYACFVSNLATQR 377 2174 2052 30 2351 6065 3247 37 10
9019.0141 YACFVSNLATGRNNS 4520 217 2339 107 1237 -- 1509 17 9
9019.0142 469 200 1328 4.4 274 15,808 26 2280 12 9019.0006
HQLLCCEVETTRRAY 5607 3471 5545 349 325 -- 60 2016 7 9019.0012 1066
36 1121 700 336 -- 106 2013 8 9019.0150 LPSNRKIVATWMLEV 137 886 145
8.5 7.1 8449 50 47 13 9019.0153 VFPLAMNYLDRFLSL 19,713 27 78 5.4 39
239 2.6 2005 10 9019.0007 DRFLSLEPVKKSRLQ 18,378 46 4128 -- 394 --
359 3.0 10 9019.0156 RLQLLGATCMFVASK -- 831 713 227 277 -- 421 504
10 1622.06 LLQMELLLVNKLKWN 6097 187 1305 44 28 -- 321 39 9
9019.0163 MELLLVNKLKWNLAA 3090 46 162 4.9 246 -- 30 13 10 9019.0164
VNKLKWNLAAMTPHD 449 1043 115 3.0 356 586 1839 2519 10 9019.0165
4876 11,907 194 332 356 -- 576 41 8 9019.0167 NKQTRKIIAQTFVAL 236
34 3.9 1.2 3.3 342 8.7 23 15 9019.0168 AQIIVALCATDVRFI 536 276 132
219 97 -- 46 18 14 9019.0169 752 88 21 24 84 5299 290 826 13
9019.0170 PPSMVAAGSVVAAVQ 301 10,090 55 26 -- 91 957 10 9019.0171
VAAVQGLNLRSPNNF -- 11,089 2018 171 1205 -- 296 3541 6 9019.0030
NLELTYLPTNASLSF 3055 30 141 105 23 -- 29 189 12 9019.0031
LTYLPTNASLSELQD 4061 213 157 47 112 141 1631 173 12 9019.0032 302
165 3438 103 75 13,508 546 1361 11 9019.0033 YVLIAHNQVRQVPLQ 358
208 302 1.9 679 649 124 18 14 9019.0034 HNQVRQVPLQRLRIV 6644 21 42
270 340 -- 18 173 12 9019.0035 221 84 81 12 9019.0046
LREVRAVTSANIQEF 5187 661 162 1.5 27 -- 163 94 12 9019.0052
LSVFQNLQVIRGRIL 859 9.6 488 80 33 -- 67 17 14 9019.0054 430 773 40
1.3 5.4 358 562 82 13 9019.0057 LRSLRELGSGLALIH 594 309 495 16 24
16,142 549 726 12 9019.0009 -- 12 17 165 -- 36 12 9019.0079
SRLLGPCLTSTVQLV 137 80 445 4.7 39 3567 481 392 13 9019.0087
PIKWMALESILRRRF 3620 133 66 3.3 -- 62 13 9019.0003 IKWMALESILRRRFT
9282 136 241 1118 11 -- 340 3.3 10 9019.0004 FSRMARDPQRFVVIQ 1481
49 6367 240 1404 -- 227 45 10 9019.0174 ALPLPPPPLLPLLPL -- 41 1337
1524 263 16,239 40 9665 8 9019.0175 PPPLLPLLPLLLLLL 307 121 23 1322
5.0 -- 2.1 121 12 9019.0176 LLPLLPLLLLLLGAS 5803 498 120 2002 182
-- 19 2390 10 9019.0177 PLLLLLLGASGGGGG -- 12,818 18,255 2164 252
-- 314 -- 4 9019.0180 317 -- -- 237 1371 -- 1888 -- 5
9019.0185 -- 163 1768 4974 91 -- 417 843 9 9019.0189
LDQVLERISTMRLPD 52 467 314 1052 84 -- 367 223 12 9019.0190
EROPLEHLYSLHIPN 638 1993 50 1149 23 -- 1648 4000 8 9019.0191
GLYNLKQCKMSLNGQ 9434 2000 413 501 223 -- 1613 5009 6 9019.0192
TGKLIQGAPTIRGDP 1709 7939 2991 927 1731 2191 465 36 9 -- indicates
binding affinity .gtoreq. 20.000 nM. indicates data missing or
illegible when filed
TABLE-US-00004 TABLE III Vaccine Candidates DRB1 DRB1 DRB1 DRB1
DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB3 DRB4 DRB5 EPITOPE %
*0101 *0301 *0401 *0404 *0405 *0701 *0802 *0901 *1101 *1201 *1302
*1501 *0101 *0101 *0101 HER2/NEU.59 15 X X X X X X X X X X X X
HER2/NEU.885 25 X X X X X X X X X X X X CEA.24 17 X X X X X X X X X
X CEA.653 25 X X X X X X X IGFBP2.17 19 X X X X X X X X IGFBP2.249
23 X X X X X X X CYCLIND1.53 13 X X X X X X X X X X X CYCLIND1.199
13 X X X X X X X X X % = Percent of patients with responses
Sequence CWU 1
1
198114PRTClostridium tetani 1Gln Tyr Ile Lys Ala Asn Ser Lys Phe
Ile Gly Ile Thr Glu 1 5 10 221PRTPlasmodium falciparum 2Asp Ile Glu
Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe 1 5 10 15 Asn
Val Val Asn Ser 20 317PRTStreptococcus sp. 3Tyr Gly Ala Val Asp Ser
Ile Leu Gly Gly Val Ala Thr Tyr Gly Ala 1 5 10 15 Ala
413PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 4Ala Lys Xaa Val Trp Ala Asn Thr Leu Lys Ala Ala
Ala 1 5 10 515PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 5Arg Trp Cys Ile Pro Trp Gln Arg Leu Leu
Leu Thr Ala Ser Leu 1 5 10 15 615PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 6Leu Leu Thr Phe Trp Asn
Pro Pro Thr Thr Ala Lys Leu Thr Ile 1 5 10 15 715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 7Thr
Ala Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu 1 5 10 15
815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 8Glu Val Leu Leu Leu Val His Asn Leu Pro Gln His
Leu Phe Gly 1 5 10 15 915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 9Tyr Ser Trp Tyr Lys Gly Glu
Arg Val Asp Gly Asn Arg Gln Ile 1 5 10 15 1015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 10Asn
Arg Gln Ile Ile Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr 1 5 10 15
1115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 11Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly
Pro Ala Tyr 1 5 10 15 1215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 12Gly Pro Ala Tyr Ser Gly Arg
Glu Ile Ile Tyr Pro Asn Ala Ser 1 5 10 15 1315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 13Gly
Arg Glu Ile Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn 1 5 10 15
1415PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 14Asp Thr Gly Phe Tyr Thr Leu His Val Ile Lys Ser
Asp Leu Val 1 5 10 15 1515PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 15Phe Tyr Thr Leu His Val Ile
Lys Ser Asp Leu Val Asn Glu Glu 1 5 10 15 1615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 16Leu
His Val Ile Lys Ser Asp Leu Val Asn Glu Glu Ala Thr Gly 1 5 10 15
1715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 17Lys Ser Asp Leu Val Asn Glu Glu Ala Thr Gly Gln
Phe Arg Val 1 5 10 15 1815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 18Gln Phe Arg Val Tyr Pro Glu
Leu Pro Lys Pro Ser Ile Ser Ser 1 5 10 15 1915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 19Lys
Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro Val Glu Asp Lys 1 5 10 15
2015PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 20Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val
Ser Pro Arg 1 5 10 15 2115PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 21Ser Asp Ser Val Ile Leu Asn
Val Leu Tyr Gly Pro Asp Ala Pro 1 5 10 15 2215PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 22Leu
Asn Val Leu Tyr Gly Pro Asp Ala Pro Thr Ile Ser Pro Leu 1 5 10 15
2315PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 23Ala Pro Thr Ile Ser Pro Leu Asn Thr Ser Tyr Arg
Ser Gly Glu 1 5 10 15 2415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 24Gln Tyr Ser Trp Phe Val Asn
Gly Thr Phe Gln Gln Ser Thr Gln 1 5 10 15 2515PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 25Gln
Glu Leu Phe Ile Pro Asn Ile Thr Val Asn Asn Ser Gly Ser 1 5 10 15
2615PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 26Arg Thr Thr Val Thr Thr Ile Thr Val Tyr Ala Glu
Pro Pro Lys 1 5 10 15 2715PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 27Thr Ile Thr Val Tyr Ala Glu
Pro Pro Lys Pro Phe Ile Thr Ser 1 5 10 15 2815PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 28Ser
Asp Pro Val Ile Leu Asn Val Leu Tyr Gly Pro Asp Asp Pro 1 5 10 15
2915PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 29Ser Tyr Thr Tyr Tyr Arg Pro Gly Val Asn Leu Ser
Leu Ser Cys 1 5 10 15 3015PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 30Tyr Ser Trp Leu Ile Asp Gly
Asn Ile Gln Gln His Thr Gln Glu 1 5 10 15 3115PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 31Asn
Ser Gly Leu Tyr Thr Cys Gln Ala Asn Asn Ser Ala Ser Gly 1 5 10 15
3215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 32Arg Thr Thr Val Lys Thr Ile Thr Val Ser Ala Glu
Leu Pro Lys 1 5 10 15 3315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 33Thr Ile Thr Val Ser Ala Glu
Leu Pro Lys Pro Ser Ile Ser Ser 1 5 10 15 3415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 34Tyr
Leu Trp Trp Val Asn Gly Gln Ser Leu Pro Val Ser Pro Arg 1 5 10 15
3515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 35Val Cys Gly Ile Gln Asn Ser Val Ser Ala Asn Arg
Ser Asp Pro 1 5 10 15 3615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 36Gln Asn Ser Val Ser Ala Asn
Arg Ser Asp Pro Val Thr Leu Asp 1 5 10 15 3715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 37Ser
Ser Tyr Leu Ser Gly Ala Asn Leu Asn Leu Ser Cys His Ser 1 5 10 15
3815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 38Gln Tyr Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln
His Thr Gln 1 5 10 15 3915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 39Ile Asn Gly Ile Pro Gln Gln
His Thr Gln Val Leu Phe Ile Ala 1 5 10 15 4015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 40Asn
Gly Thr Tyr Ala Cys Phe Val Ser Asn Leu Ala Thr Gly Arg 1 5 10 15
4115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 41Tyr Ala Cys Phe Val Ser Asn Leu Ala Thr Gly Arg
Asn Asn Ser 1 5 10 15 4215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 42Asn Asn Ser Ile Val Lys Ser
Ile Thr Val Ser Ala Ser Gly Thr 1 5 10 15 4315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 43Ser
Ile Thr Val Ser Ala Ser Gly Thr Ser Pro Gly Leu Ser Ala 1 5 10 15
4415PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 44Ser Pro Gly Leu Ser Ala Gly Ala Thr Val Gly Ile
Met Ile Gly 1 5 10 15 4515PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 45Thr Val Gly Ile Met Ile Gly
Val Leu Val Gly Val Ala Leu Ile 1 5 10 15 4615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 46His
Gln Leu Leu Cys Cys Glu Val Glu Thr Ile Arg Arg Ala Tyr 1 5 10 15
4715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 47Asp Ala Asn Leu Leu Asn Asp Arg Val Leu Arg Ala
Met Leu Lys 1 5 10 15 4815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 48Asn Asp Arg Val Leu Arg Ala
Met Leu Lys Ala Glu Glu Thr Cys 1 5 10 15 4915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 49Arg
Ala Met Leu Lys Ala Glu Glu Thr Cys Ala Pro Ser Val Ser 1 5 10 15
5015PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 50Phe Lys Cys Val Gln Lys Glu Val Leu Pro Ser Met
Arg Lys Ile 1 5 10 15 5115PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 51Gln Lys Glu Val Leu Pro Ser
Met Arg Lys Ile Val Ala Thr Trp 1 5 10 15 5215PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 52Leu
Pro Ser Met Arg Lys Ile Val Ala Thr Trp Met Leu Glu Val 1 5 10 15
5315PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 53Met Arg Lys Ile Val Ala Thr Trp Met Leu Glu Val
Cys Glu Glu 1 5 10 15 5415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 54Met Leu Glu Val Cys Glu Glu
Gln Lys Cys Glu Glu Glu Val Phe 1 5 10 15 5515PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 55Glu
Glu Glu Val Phe Pro Leu Ala Met Asn Tyr Leu Asp Arg Phe 1 5 10 15
5615PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 56Val Phe Pro Leu Ala Met Asn Tyr Leu Asp Arg Phe
Leu Ser Leu 1 5 10 15 5715PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 57Asp Arg Phe Leu Ser Leu Glu
Pro Val Lys Lys Ser Arg Leu Gln 1 5 10 15 5815PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 58Leu
Glu Pro Val Lys Lys Ser Arg Leu Gln Leu Leu Gly Ala Thr 1 5 10 15
5915PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 59Arg Leu Gln Leu Leu Gly Ala Thr Cys Met Phe Val
Ala Ser Lys 1 5 10 15 6015PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 60Thr Cys Met Phe Val Ala Ser
Lys Met Lys Glu Thr Ile Pro Leu 1 5 10 15 6115PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 61Ala
Ser Lys Met Lys Glu Thr Ile Pro Leu Thr Ala Glu Lys Leu 1 5 10 15
6215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 62Thr Ile Pro Leu Thr Ala Glu Lys Leu Cys Ile Tyr
Thr Asp Asn 1 5 10 15 6315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 63Lys Leu Cys Ile Tyr Thr Asp
Asn Ser Ile Arg Pro Glu Glu Leu 1 5 10 15 6415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 64Asp
Asn Ser Ile Arg Pro Glu Glu Leu Leu Gln Met Glu Leu Leu 1 5 10 15
6515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 65Pro Glu Glu Leu Leu Gln Met Glu Leu Leu Leu Val
Asn Lys Leu 1 5 10 15 6615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 66Glu Glu Leu Leu Gln Met Glu
Leu Leu Leu Val Asn Lys Leu Lys 1 5 10 15 6715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 67Leu
Leu Gln Met Glu Leu Leu Leu Val Asn Lys Leu Lys Trp Asn 1 5 10 15
6815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 68Met Glu Leu Leu Leu Val Asn Lys Leu Lys Trp Asn
Leu Ala Ala 1 5 10 15 6915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 69Val Asn Lys Leu Lys Trp Asn
Leu Ala Ala Met Thr Pro His Asp 1 5 10 15 7015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 70Lys
Trp Asn Leu Ala Ala Met Thr Pro His Asp Phe Ile Glu His 1 5 10 15
7115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 71Trp Asn Leu Ala Ala Met Thr Pro His Asp Phe Ile
Glu His Phe 1 5 10 15 7215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 72Pro His Asp Phe Ile Glu His
Phe Leu Ser Lys Met Pro Glu Ala 1 5 10 15 7315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 73Asn
Lys Gln Ile Ile Arg Lys His Ala Gln Thr Phe Val Ala Leu 1 5 10 15
7415PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 74Ala Gln Thr Phe Val Ala Leu Cys Ala Thr Asp Val
Lys Phe Ile 1 5 10 15 7515PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 75Val Lys Phe Ile Ser Asn Pro
Pro Ser Met Val Ala Ala Gly Ser 1 5 10 15 7615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 76Pro
Pro Ser Met Val Ala Ala Gly Ser Val Val Ala Ala Val Gln 1 5 10 15
7715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 77Val Ala Ala Val Gln Gly Leu Asn Leu Arg Ser Pro
Asn Asn Phe 1 5 10 15 7815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 78Ile Glu Ala Leu Leu Glu Ser
Ser Leu Arg Gln Ala Gln Gln Asn 1 5 10 15 7915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 79Glu
Ala Leu Leu Glu Ser Ser Leu Arg Gln Ala Gln Gln Asn Met 1 5 10 15
8015PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 80Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala
Leu Leu Pro 1 5 10 15 8115PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 81Trp Gly Leu Leu Leu Ala Leu
Leu Pro Pro Gly Ala Ala Ser Thr 1 5 10 15 8215PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 82Leu
Leu Ala Leu Leu Pro Pro Gly Ala Ala Ser Thr Gln Val Cys 1 5 10 15
8315PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 83Gly Thr Asp Met Lys Leu Arg Leu Pro Ala Ser Pro
Glu Thr His 1 5 10 15 8415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 84Arg His Leu Tyr Gln Gly Cys
Gln Val Val Gln Gly Asn Leu Glu 1 5 10 15 8515PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide
85Gly
Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr Leu Pro 1 5 10 15
8615PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 86Asn Leu Glu Leu Thr Tyr Leu Pro Thr Asn Ala Ser
Leu Ser Phe 1 5 10 15 8715PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 87Leu Thr Tyr Leu Pro Thr Asn
Ala Ser Leu Ser Phe Leu Gln Asp 1 5 10 15 8815PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 88Ile
Gln Glu Val Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val 1 5 10 15
8915PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 89Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val
Pro Leu Gln 1 5 10 15 9015PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 90His Asn Gln Val Arg Gln Val
Pro Leu Gln Arg Leu Arg Ile Val 1 5 10 15 9115PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 91Val
Arg Gln Val Pro Leu Gln Arg Leu Arg Ile Val Arg Gly Thr 1 5 10 15
9215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 92Gly Thr Gln Leu Phe Glu Asp Asn Tyr Ala Leu Ala
Val Leu Asp 1 5 10 15 9315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 93Gly Asp Pro Leu Asn Asn Thr
Thr Pro Val Thr Gly Ala Ser Pro 1 5 10 15 9415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 94Thr
Thr Pro Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu 1 5 10 15
9515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 95Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser Leu
Thr Glu Ile 1 5 10 15 9615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 96Thr Glu Ile Leu Lys Gly Gly
Val Leu Ile Gln Arg Asn Pro Gln 1 5 10 15 9715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 97Gly
Gly Val Leu Ile Gln Arg Asn Pro Gln Leu Cys Tyr Gln Asp 1 5 10 15
9815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 98Asn Pro Gln Leu Cys Tyr Gln Asp Thr Ile Leu Trp
Lys Asp Ile 1 5 10 15 9915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 99Ile Cys Glu Leu His Cys Pro
Ala Leu Val Thr Tyr Asn Thr Asp 1 5 10 15 10015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 100Ser
Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn 1 5 10 15
10115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 101Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu
Val Arg Ala Val 1 5 10 15 10215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 102Met Glu His Leu Arg Glu
Val Arg Ala Val Thr Ser Ala Asn Ile 1 5 10 15 10315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 103Leu
Arg Glu Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe 1 5 10 15
10415PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 104Cys Lys Lys Ile Phe Gly Ser Leu Ala Phe Leu
Pro Glu Ser Phe 1 5 10 15 10515PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 105Pro Glu Ser Phe Asp Gly
Asp Pro Ala Ser Asn Thr Ala Pro Leu 1 5 10 15 10615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 106Thr
Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe Glu Thr Leu 1 5 10 15
10715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 107Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro
Asp Ser Leu Pro 1 5 10 15 10815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 108Pro Asp Ser Leu Pro Asp
Leu Ser Val Phe Gln Asn Leu Gln Val 1 5 10 15 10915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 109Leu
Ser Val Phe Gln Asn Leu Gln Val Ile Arg Gly Arg Ile Leu 1 5 10 15
11015PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 110Asn Leu Gln Val Ile Arg Gly Arg Ile Leu His
Asn Gly Ala Tyr 1 5 10 15 11115PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 111Arg Gly Arg Ile Leu His
Asn Gly Ala Tyr Ser Leu Thr Leu Gln 1 5 10 15 11215PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 112Ser
Leu Thr Leu Gln Gly Leu Gly Ile Ser Trp Leu Gly Leu Arg 1 5 10 15
11315PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 113Gly Leu Gly Ile Ser Trp Leu Gly Leu Arg Ser
Leu Arg Glu Leu 1 5 10 15 11415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 114Leu Arg Ser Leu Arg Glu
Leu Gly Ser Gly Leu Ala Leu Ile His 1 5 10 15 11515PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 115Gly
Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His 1 5 10 15
11615PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 116Asn Thr His Leu Cys Phe Val His Thr Val Pro
Trp Asp Gln Leu 1 5 10 15 11715PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 117Asp Glu Cys Val Gly Glu
Gly Leu Ala Cys His Gln Leu Cys Ala 1 5 10 15 11815PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 118Gly
His Cys Trp Gly Pro Gly Pro Thr Gln Cys Val Asn Cys Ser 1 5 10 15
11915PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 119Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu
Glu Cys Arg Val 1 5 10 15 12015PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 120Glu Cys Arg Val Leu Gln
Gly Leu Pro Arg Glu Tyr Val Asn Ala 1 5 10 15 12115PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 121Leu
Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys Leu 1 5 10 15
12215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 122Pro Ser Gly Val Lys Pro Asp Leu Ser Tyr Met
Pro Ile Trp Lys 1 5 10 15 12315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 123Ala Ser Pro Leu Thr Ser
Ile Ile Ser Ala Val Val Gly Ile Leu 1 5 10 15 12415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 124Ile
Ser Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val 1 5 10 15
12515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 125Ile Leu Leu Val Val Val Leu Gly Val Val Phe
Gly Ile Leu Ile 1 5 10 15 12615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 126Val Leu Gly Val Val Phe
Gly Ile Leu Ile Lys Arg Arg Gln Gln 1 5 10 15 12715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 127Gln
Gln Lys Ile Arg Lys Tyr Thr Met Arg Arg Leu Leu Gln Glu 1 5 10 15
12815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 128Ile Arg Lys Tyr Thr Met Arg Arg Leu Leu Gln
Glu Thr Glu Leu 1 5 10 15 12915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 129Met Arg Ile Leu Lys Glu
Thr Glu Leu Arg Lys Val Lys Val Leu 1 5 10 15 13015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 130Glu
Thr Glu Leu Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe 1 5 10 15
13115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 131Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly
Thr Val Tyr Lys 1 5 10 15 13215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 132Gly Glu Asn Val Lys Ile
Pro Val Ala Ile Lys Val Leu Arg Glu 1 5 10 15 13315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 133Lys
Ile Pro Val Ala Ile Lys Val Leu Arg Glu Asn Thr Ser Pro 1 5 10 15
13415PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 134Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr
Val Ser Arg Leu 1 5 10 15 13515PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 135Met Ala Gly Val Gly Ser
Pro Tyr Val Ser Arg Leu Leu Gly Ile 1 5 10 15 13615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 136Ser
Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val 1 5 10 15
13715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 137Thr Val Gln Leu Val Thr Gln Leu Met Pro Tyr
Gly Cys Leu Leu 1 5 10 15 13815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 138Arg Gly Arg Leu Gly Ser
Gln Asp Leu Leu Asn Trp Cys Met Gln 1 5 10 15 13915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 139Leu
Leu Asn Trp Cys Met Gln Ile Ala Lys Gly Met Ser Tyr Leu 1 5 10 15
14015PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 140Cys Met Gln Ile Ala Lys Gly Met Ser Tyr Leu
Glu Asp Val Arg 1 5 10 15 14115PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 141Gly Met Ser Tyr Leu Glu
Asp Val Arg Leu Val His Arg Asp Leu 1 5 10 15 14215PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 142Val
Arg Leu Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val 1 5 10 15
14315PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 143His Arg Asp Leu Ala Ala Arg Asn Val Leu Val
Lys Ser Pro Asn 1 5 10 15 14415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 144Ala Arg Asn Val Leu Val
Lys Ser Pro Asn His Val Lys Ile Thr 1 5 10 15 14515PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 145Pro
Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg Arg Arg Phe 1 5 10 15
14615PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 146Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg
Arg Arg Phe Thr 1 5 10 15 14715PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 147Glu Ser Ile Leu Arg Arg
Arg Phe Thr His Gln Ser Asp Val Trp 1 5 10 15 14815PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 148Ser
Asp Val Trp Ser Tyr Gly Val Thr Val Trp Glu Leu Met Thr 1 5 10 15
14915PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 149Gly Val Thr Val Trp Glu Leu Met Thr Phe Gly
Ala Lys Pro Tyr 1 5 10 15 15015PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 150Val Trp Glu Leu Met Thr
Phe Gly Ala Lys Pro Tyr Asp Gly Ile 1 5 10 15 15115PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 151Ala
Lys Pro Tyr Asp Gly Ile Pro Ala Arg Glu Ile Pro Asp Leu 1 5 10 15
15215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 152Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val
Lys Cys Trp Met 1 5 10 15 15315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 153Asp Val Tyr Met Ile Met
Val Lys Cys Trp Met Ile Asp Ser Glu 1 5 10 15 15415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 154Arg
Pro Arg Phe Arg Glu Leu Val Ser Glu Phe Ser Arg Met Ala 1 5 10 15
15515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 155Phe Arg Glu Leu Val Ser Glu Phe Ser Arg Met
Ala Arg Asp Pro 1 5 10 15 15615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 156Phe Ser Arg Met Ala Arg
Asp Pro Gln Arg Phe Val Val Ile Gln 1 5 10 15 15715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 157Asp
Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu 1 5 10 15
15815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 158Ala Lys Gly Leu Gln Ser Leu Pro Thr His Asp
Pro Ser Pro Leu 1 5 10 15 15915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 159Leu Gln Arg Tyr Ser Glu
Asp Pro Thr Val Pro Leu Pro Ser Glu 1 5 10 15 16015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 160Pro
Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser 1 5 10 15
16115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 161Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly
Ala Thr Leu Glu 1 5 10 15 16215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 162Gly Ala Thr Leu Glu Arg
Pro Lys Thr Leu Ser Pro Gly Lys Asn 1 5 10 15 16315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 163Lys
Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr 1 5 10 15
16415PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 164Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu
Pro Pro Pro Pro 1 5 10 15 16515PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 165Ala Leu Pro Leu Pro Pro
Pro Pro Leu Leu Pro Leu Leu Pro Leu 1 5 10 15 16615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 166Pro
Pro Pro Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Leu 1 5 10 15
16715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 167Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu
Leu Gly Ala Ser 1 5 10 15 16815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 168Pro Leu Leu Leu Leu Leu
Leu Gly Ala Ser Gly Gly Gly Gly Gly 1 5 10 15
16915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 169Ala
Glu Val Leu Phe Arg Cys Pro Pro Cys Thr Pro Glu Arg Leu 1 5 10 15
17015PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 170Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro
Val Ala Pro Pro 1 5 10 15 17115PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 171Pro Pro Pro Val Ala Pro
Pro Ala Ala Val Ala Ala Val Ala Gly 1 5 10 15 17215PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 172Gly
Ala Arg Met Pro Cys Ala Glu Leu Val Arg Glu Pro Gly Cys 1 5 10 15
17315PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 173Cys Ala Glu Leu Val Arg Glu Pro Gly Cys Gly
Cys Cys Ser Val 1 5 10 15 17415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 174Cys Ala Arg Leu Glu Gly
Glu Ala Cys Gly Val Tyr Thr Pro Arg 1 5 10 15 17515PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 175Glu
Leu Pro Leu Gln Ala Leu Val Met Gly Glu Gly Thr Cys Glu 1 5 10 15
17615PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 176Gln Ala Leu Val Met Gly Glu Gly Thr Cys Glu
Lys Arg Arg Asp 1 5 10 15 17715PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 177Ser Glu Gly Gly Leu Val
Glu Asn His Val Asp Ser Thr Met Asn 1 5 10 15 17815PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 178Thr
Met Asn Met Leu Gly Gly Gly Gly Ser Ala Gly Arg Lys Pro 1 5 10 15
17915PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 179Leu Lys Ser Gly Met Lys Glu Leu Ala Val Phe
Arg Glu Lys Val 1 5 10 15 18015PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 180Lys Glu Leu Ala Val Phe
Arg Glu Lys Val Thr Glu Gln His Arg 1 5 10 15 18115PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 181Glu
Leu Ala Val Phe Arg Glu Lys Val Thr Glu Gln His Arg Gln 1 5 10 15
18215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 182Arg Glu Lys Val Thr Glu Gln His Arg Gln Met
Gly Lys Gly Gly 1 5 10 15 18315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 183Gly Lys His His Leu Gly
Leu Glu Glu Pro Lys Lys Leu Arg Pro 1 5 10 15 18415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 184Lys
His His Leu Gly Leu Glu Glu Pro Lys Lys Leu Arg Pro Pro 1 5 10 15
18515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 185Glu Pro Lys Lys Leu Arg Pro Pro Pro Ala Arg
Thr Pro Cys Gln 1 5 10 15 18615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 186Leu Asp Gln Val Leu Glu
Arg Ile Ser Thr Met Arg Leu Pro Asp 1 5 10 15 18715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 187Thr
Met Arg Leu Pro Asp Glu Arg Gly Pro Leu Glu His Leu Tyr 1 5 10 15
18815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 188Glu Arg Gly Pro Leu Glu His Leu Tyr Ser Leu
His Ile Pro Asn 1 5 10 15 18915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 189Gly Leu Tyr Asn Leu Lys
Gln Cys Lys Met Ser Leu Asn Gly Gln 1 5 10 15 19015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 190Thr
Gly Lys Leu Ile Gln Gly Ala Pro Thr Ile Arg Gly Asp Pro 1 5 10 15
19115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 191Ala Pro Thr Ile Arg Gly Asp Pro Glu Cys His
Leu Phe Tyr Asn 1 5 10 15 19215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 192Cys His Leu Phe Tyr Asn
Glu Gln Gln Glu Ala Arg Gly Val His 1 5 10 15 1935PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 193Gly
Pro Gly Pro Gly 1 5 1945PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 194Pro Gly Pro Gly Pro 1 5
19522PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 195Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly
Pro Gly Pro Gly Pro 1 5 10 15 Gly Pro Gly Pro Gly Pro 20
19622PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 196Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro
Gly Pro Gly Pro Gly 1 5 10 15 Pro Gly Pro Gly Pro Gly 20
19723PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 197Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly
Pro Gly Pro Gly Pro 1 5 10 15 Gly Pro Gly Pro Gly Pro Gly 20
19823PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 198Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro
Gly Pro Gly Pro Gly 1 5 10 15 Pro Gly Pro Gly Pro Gly Pro 20
* * * * *